



Published in final edited form as:

J Med Chem. 2006 December 14; 49(25): 7373–7383. doi:10.1021/jm0608208.

2-Triazole-Substituted Adenosines: A New Class of Selective A₃ Adenosine Receptor Agonists, Partial Agonists, and Antagonists

Liesbet Cosyn[†], Krishnan K. Palaniappan[‡], Soo-Kyung Kim[‡], Heng T. Duong[‡], Zhan-Guo Gao[‡], Kenneth A. Jacobson^{*‡}, and Serge Van Calenbergh^{*†}

Laboratory for Medicinal Chemistry, Faculty of Pharmaceutical Sciences (FFW), Ghent University, Harelbekestraat 72, B-9000 Ghent, Belgium, and Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892

Abstract

“Click chemistry” was explored to synthesize two series of 2-(1,2,3-triazolyl)adenosine derivatives (**1–14**). Binding affinity at the human A₁, A_{2A}, and A₃ARs (adenosine receptors) and relative efficacy at the A₃AR were determined. Some triazol-1-yl analogues showed A₃AR affinity in the low nanomolar range, a high ratio of A₃/A_{2A} selectivity, and a moderate-to-high A₃/A₁ ratio. The 1,2,3-triazol-4-yl regiomers typically showed decreased A₃AR affinity. Sterically demanding groups at the adenine C2 position tended to reduce relative A₃AR efficacy. Thus, several 5'-OH derivatives appeared to be selective A₃AR antagonists, i.e., **10**, with 260-fold binding selectivity in comparison to the A₁AR and displaying a characteristic docking mode in an A₃AR model. The corresponding 5'-ethyluronamide analogues generally showed increased A₃AR affinity and behaved as full agonists, i.e., **17**, with 910-fold A₃/A₁ selectivity. Thus, N⁶-substituted 2-(1,2,3-triazolyl)-adenosine analogues constitute a novel class of highly potent and selective nucleoside-based A₃AR antagonists, partial agonists, and agonists.

Introduction

Adenosine receptors (AR) are G-protein-coupled receptors and consist of four subtypes classified as A₁, A_{2A}, A_{2B}, and A₃. Among the four AR subtypes, the A₃AR is the most recently identified.¹ The distribution of A₃AR is species-dependent, and in humans this subtype occurs in the lungs, liver, heart, kidneys, and brain.^{2–4} Activation of this receptor subtype inhibits adenylyl cyclase activity, increases phosphatidylinositol-specific phospholipase C activity, and stimulates Ca²⁺ mobilization.³ Adenosine A₃ receptor stimulation induces cardioprotection through the activation of K_{ATP} channels⁴ and is also involved in neuroprotection, suggesting the possibility of using A₃AR agonists to treat cardiac and cerebral ischemia.⁵ A₃AR agonists also exhibit systemic anticancer and

^{*}To whom correspondence should be addressed. For K.A.J.: phone, 301-496-9024; fax, 301-480-8422; kajacobs@helix.nih.gov. For S.V.C.: phone, +32(0)9 264 81 24; fax, +32(0)9 264 81 46; serge.vancalenbergh@ugent.be.

[†]Ghent University.

[‡]National Institutes of Health.

Supporting Information Available: Elemental analysis data for compounds **1–20**, **23**, **31**, and **33**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

chemoprotective effects.⁶ A₃AR modulators have been proposed as antiinflammatory and antiasthmatic drugs.^{7,8} Selective A₃AR antagonists promise to be useful in the regulation of cell growth^{8,9} and as cerebroprotective agents.^{10,11} They also seem to enhance anticancer treatment by counteracting P-glycoprotein efflux in multidrug resistance.¹² A₃AR antagonists are also proposed as potential therapeutics for the treatment of glaucoma; application of A₃-AR antagonists externally to the eye substantially lowers intraocular pressure in mice and monkeys.^{13–15}

Although diverse in structure, most AR antagonists share some common structural features. In general, they are planar, aromatic, or π -electron-rich and nitrogen-containing heterocycles. Additionally, most AR antagonists lack the ribose moiety, which seems essential for agonist activity.¹⁶ Various heterocyclic classes have been identified as promising leads for A₃AR antagonists, among them 1,4-dihydropyridines, pyridines, deazaadenines, pyrazolopyrimidines, adenines, and 1,2,4-triazolo[4,3-*a*]quinoxalin-1-ones.^{4,7,17,18}

However, the A₃AR, more than other AR subtypes, is amenable to the design of nucleoside-based antagonists. The efficacy of nucleoside derivatives in activation of the A₃AR is particularly sensitive to molecular substitution of the ligand.¹⁹ A wide range of adenosine derivatives have been shown to antagonize this receptor, including the highly potent A₁AR agonist 2-chloro-*N*⁶-cyclopentyladenosine. *N*⁶-Benzyl groups are associated with reduced A₃AR efficacy, leading to partial agonists and antagonists. However, many of the nucleosides so far demonstrated to be antagonists of the A₃AR are not highly subtype-selective.²⁰ Nucleoside-based A₃AR antagonists maintaining an intact ribose moiety were reported by Volpini et al.,²¹ with a series of 8-alkynyladenosine derivatives that exhibited A₃AR selectivity, but suffered from weak A₃AR affinity. A spiro lactam derivative, in which the 5'-alkyluronamide group was cyclized onto the 4' carbon, was found to potently and selectively antagonize the A₃AR.^{15,19} An advantage of nucleoside-based A₃AR antagonists over other heterocyclic antagonists is the ability to achieve high affinity at murine species.

Recently, researchers from CV Therapeutics described a series of 2-pyrazolyladenosine analogues.²² Several representative compounds containing an *N*⁶-methyl substituent proved to display high affinity and selectivity for the A₃AR. This study confirms the former finding²³ that introduction of a methyl group into the *N*⁶ position increases the affinity for the human A₃AR and enhances the selectivity versus A₁ and A_{2A}ARs. On the basis of these results, we explored the versatile “click chemistry” approach²⁴ to synthesize two series of *N*⁶-methyl-2-(1,2,3-triazolyl)adenosine derivatives and evaluated their affinity, selectivity, and efficacy at the A₃AR. Although a number of 1,2,3-triazole nucleoside derivatives have been described,²⁵ most involve base replacement with 1,2,3-triazole or introduction of 1,2,3-triazole at C8 or at the sugar moiety.

Results and Discussion

Chemistry

The synthesis of the 1,2,3-triazol-1-yladenosine derivatives is depicted in Scheme 1. 2-Iodo-*N*⁶-methyladenosine **22**²³ was prepared by reacting **21**²⁶ with 2.0 M CH₃NH₂ in THF. Since

the reaction conditions²⁷ for a Cu(I)-catalyzed nucleophilic substitution are very similar to those used in the “click” variant of Huisgen’s 1,3-dipolar cycloaddition, we initially attempted to perform a one-pot conversion of **22** to the desired 1,4-disubstituted 1,2,3-triazoles. The 2-azido derivative **23** was isolated as the main reaction product, and only a minor amount of the appropriate triazole was formed. This event forced us to perform the reaction in two steps. First the azido intermediate **23** was prepared in 66% yield from **22**. ¹H and ¹³C NMR in DMSO-*d*₆ proved the presence of a tautomeric fused tetrazole form (17%) of the 2-azidoadenosine derivative **23**, due to a spontaneous cyclization (Scheme 2). Such azido/tetrazole tautomerism has been previously reported for 2-azidoadenine and for 2-azidoadenosine.^{28,29} Next we applied a Cu(I)-catalyzed 1,3-cycloaddition reaction of azide **23** with the appropriate alkyne to generate the triazole analogues **1–11** (Scheme 1).³⁰ Generally, the use of a water/butanol mixture as a solvent for the 1,3-cycloaddition allowed simple isolation of the desired compounds, which precipitated from the reaction medium.

Similarly, the 1,2,3-triazol-4-yl analogues **12–14** (Scheme 3) were prepared by a Cu⁺-catalyzed Huisgen 1,3-dipolar cycloaddition reaction of 2-ethynyl-*N*⁶-methyladenosine (**25**) with the appropriate azide.

The synthesis of the 5'-*N*-ethylcarbamoyl 2-(1,2,3)-triazol-1-yladenosine analogues **15–19** was carried out starting from 2-iodo-9-(2',3'-*O*-isopropylidene- β -D-ribofuranosyl)-*N*⁶-methyladenine (**26**). After permanganate oxidation, carboxylic acid **27** was converted into its *p*-nitrophenyl ester **28**, which upon treatment with ethylamine gave uronamide **29**. Deprotection with 80% trifluoroacetic acid yielded 5'-ethylcarbamoyl-*N*⁶-methyl-2-iodoadenosine (**30**).³⁰ The conversion of this 2-iodo derivative into the azido intermediate **31** was performed in 79% yield. The presence of a tautomeric fused tetrazole form (20%) of the 2-azidoadenosine derivative **31**, due to a spontaneous cyclization, was here also observed in the NMR spectrum. Finally we applied the Cu(I)-catalyzed 1,3-cycloaddition reaction of azide **31** with the appropriate alkyne to generate the triazole analogues **15–19** (Scheme 4).

2-Azido-*N*⁶-(5-chloro-2-methoxybenzyl)-2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-9-(β -D-ribofuranosyl)adenine (**20**) was prepared in three steps starting from intermediate **21**, as depicted in Scheme 5.

Biological Evaluation

The binding affinities of the newly synthesized adenosine derivatives were measured at the hA₁, hA_{2A}, and hA₃ARs expressed in CHO (Chinese hamster ovary) cells as previously described,²⁰ and their relative efficacy in the activation of the A₃AR was determined (Table 1). The binding affinity of more potent compounds at the ARs was evaluated with full competition curves, while the weaker compounds at the hA₁ and hA_{2A} ARs were measured at a fixed concentration of 10 μ M. Several compounds showed affinity for the A₃AR in the low nanomolar range, a very high ratio of A₃/A_{2A} selectivity, and a moderate-to-high A₃/A₁ selectivity ratio. A functional assay of A₃AR activation consisted of the ability of a single, high concentration of the nucleoside (10 μ M) to inhibit forskolin-stimulated adenylyl cyclase measured by the method of Nordstet and Fredholm,³² in comparison to the full agonist NECA (10 μ M). CI-IB-MECA (2-chloro-*N*⁶-(3-iodobenzyl)-5'-*N*-

methylcarboxamidoadenosine) was also a full agonist (100%) in this assay.¹⁹ The range of efficacies observed depended on the nature of the groups at the 2 and N⁶ positions.

The 2-azido precursor **23** showed high binding affinity at the A₃AR ($K_i = 10.8$ nM) and modest selectivity in comparison to the A₁AR. The 1,2,3-triazol-1-yl derivatives obtained by 1,3-dipolar cycloaddition of azide **23** with acetylene (**1**), butyne (**2**), and hexyne (**3**) maintained high affinity for the A₃AR and increased selectivity. They displayed K_i values of 10.4, 13.8, and 11.7 nM, respectively. Also, aromatic triazole substituents (**6**, **7**, **9**) resulted in similar K_i values of about 10 nM and even greater selectivity. Introducing nitrogen or oxygen including substituents at position 4 of the 1,2,3-triazole ring (**4**, **5**, and **8**) reduced the A₃AR affinity. Among the investigated analogues, the 4-cyclopentylmethyl derivative **10** exhibited the highest affinity for the A₃AR ($K_i = 1.3$ nM) and 260-fold selectivity in comparison to the A₁AR. Replacement of the cyclopentyl ring with a phenyl (**9**) or cyclohexyl (**11**) moiety adversely affected A₃AR affinity. Remarkably, the 1,2,3-triazol-4-yl regioisomers (**12–14**) showed decreased affinity for the A₃AR in comparison to similar 1,2,3-triazol-1-yl regioisomers. In particular, a comparison of homologous compounds **12** and **9** indicated a 6-fold loss of affinity at the A₃AR for the 4-yl isomer, approximately the same affinity at the A₁AR, and no significant measurable gain in affinity at the A_{2A}AR.

Replacement of the ribose 4'-hydroxymethyl moiety of the 2-azido derivative **23** by a 5'-*N*-ethyluronamide did not appreciably affect affinity at any of the AR subtypes. However, a similar substitution in the 2-(1,2,3-triazol-1-yl)-substituted series provided a modest (2- to 5-fold) increase in A₃AR affinity and small or no changes in A₁AR affinity, as demonstrated for the unsubstituted, 4-butyl, 4-pyridin-2-yl, and 4-benzyl substituted 1,2,3-triazol-1-yl combinations (**15**, **16**, **17**, and **18**, in comparison to **1**, **3**, **7**, and **9**, respectively). Curiously, one 5'-uronamide, compound **19**, exhibited decreased A₃AR affinity ($K_i = 11.5$ nM) compared to its potent 5'-OH analogue **10** ($K_i = 1.3$ nM).

Replacement of the N⁶-methyl substituent of the 2-azido precursor **23** by a sterically demanding 2-chloro-5-methoxybenzyl group yielded **33**, which manifested very high A₃AR affinity ($K_i = 1.4$ nM). A similar replacement of the N⁶-methyl group of an analogue **10**, also having a bulky 2-position substituent, to yield **20** reduced A₃AR affinity but not appreciably. This was in accordance with previous observations that a simultaneous substitution at the 6 and 2 positions did not improve A₃AR affinity.^{22,33} Thus, the effects of substitution at the 2 and N⁶ positions were not independent; however, it was possible to retain considerable A₃AR selectivity (46-fold in compound **20**). This was not representative of findings in a previous study in which double substitution greatly diminished the affinity and selectivity at the human A₃AR.²²

Whereas some previously synthesized 2-substituted adenosine derivatives^{22,23} displayed selective A₃AR agonist activity, all 2-triazol-1-yl-N⁶-methyladenosine analogues synthesized with an unmodified ribose moiety (**1–11** and **20**) behaved as antagonists or weak partial agonists. Similar findings were reported for 2-ester derivatives of adenosine, in which a combination of 2 and N⁶ substitution reduced efficacy.³⁴ Direct ring substitution at the 4-position of the 1,2,3-triazole with alkyl or aryl groups resulted in weak partial agonists (**1**, **2**, **4–8**), but subtle changes of structure resulted in a loss of efficacy, e.g., the 4-butyl derivative

3, 2-Triazol-1-yl- N^6 -methyladenosine analogues with a methylene spacer between the 1,2,3-triazole moiety and a ring system yielded full A_3AR antagonists (**9–11**, **20**), since they bound to the receptor but did not activate it. The 2-triazol-4-yl- N^6 -methyladenosine derivatives (**12–14**) also behaved as full A_3AR antagonists. Thus, the 5'-OH derivatives **3**, **9–14**, and **20** appeared to be A_3AR antagonists with the following order of decreasing selectivity for the A_3AR in comparison to the A_1AR : 4-cyclopentylmethyl- N^6 -methyl **10** (260-fold) > 4-butyl- N^6 -methyl **3** (72-fold), 4-cyclohexylmethyl- N^6 -methyl **11** (67-fold) > 4-cyclopentylmethyl- N^6 -(5-chloro-2-methoxybenzyl) **20**.

Interestingly, the 5'- N -ethyluronamide modification was able to reestablish the A_3AR agonist activity in analogues with sterically bulky substitution at the 2 position. This is consistent with previous findings that similar 5'-uronamides overcome the efficacy-reducing activity of substitution at the adenine 2 and N^6 positions but not at the ribose 3' position.^{19,35,36} Indeed, all 5'- N -ethyluronamide analogues studied here (**15–19**) proved to be full agonists at the A_3AR . Among them are highly selective A_3AR agonists, N^6 -methyladenosine-5'- N -ethyluronamide 2-(1,2,3-triazol-1-yl) derivatives: pyridin-2-yl **17** (910-fold) > unsubstituted **15** (280-fold) > benzyl **18** (180-fold). The 2-azido- N^6 -methyl precursors **23** and **31** also showed full agonist activity, whereas azide **33** having a bulky N^6 group showed partial agonist activity.

Selected potent agonists in this series were measured in a functional assay of the human $A_{2B}AR$. At 10 μM , compounds **3–7**, **15**, and **16** did not significantly stimulate adenylyl cyclase in human $A_{2B}AR$ -expressing CHO cells (<10% of the effect of 10 μM NECA, as a full agonist). Compounds **2**, **8–14**, **17**, **19**, and **23** at 10 μM stimulated adenylyl cyclase by <50%. Compounds **18** and **31** produced approximately 50% stimulation at 10 μM . Thus, selectivity for the A_3AR was demonstrated; these nucleosides that activate the A_3AR at low nanomolar concentrations activated the $A_{2B}AR$ only at substantial micromolar concentrations.

On the basis of previous findings, it is predicted that only the analogues containing the substituted N^6 -benzyl group (5-chloro-2-methoxy), i.e., full agonist **20** and partial agonist **33**, would be expected to bind in the nanomolar range to the rat A_3AR . Small alkyl groups at the N^6 position, such as methyl and ethyl, although conducive to high affinity at the human A_3AR , led to negligible affinity at the rat homologue of the receptor. Selected compounds were measured in binding to the rat A_3AR expressed in CHO cell membranes using [¹²⁵I]-AB-MECA. The K_i values determined were as follows: compounds **5**, **7**, and **8**, $K_i > 10 \mu M$; compound **9**, $K_i = 1.79 \mu M$; compound **10**, $K_i = 0.312 \mu M$.

Molecular Modeling

To explain the structural basis for the high binding affinity of the nucleoside 2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)- N^6 -methyl-9-(β -D-ribofuranosyl)adenine **10** at hA_3AR , we performed a computational study of ligand docking in a previously derived A_3AR model based on the high-resolution structure of bovine rhodopsin.^{37,38} Various bound conformations of the C2-substituent and χ_1 angles for the adenine ring were generated for an

energetically favorable binding location and orientation, and the resulting conformations were compared energetically in the putative binding site.

The result of docking **10** in the putative binding site of the A₃AR is shown in Figure 1A. The purine ring was surrounded by a hydrophobic pocket, defined by L91 (3.33) and L246 (6.51). In addition, the H-bonds formed between the exocyclic amine and the hydroxyl group of S247 (6.52) and between the purine N¹ atom and the side chain of N250 (6.55). The 2'-OH group of the ribose moiety formed a H-bond with the side chain of Q167 (EL2), and the 3'-OH group formed an intramolecular H-bond with the 5'-OH group. Unlike the previously reported docking models of N⁶-substituted adenosines,³⁷ here the 5'-OH group H-bonded with the side chain of H272 (7.43) and the backbone carbonyl group of S271 (7.42). The cyclopentyl moiety interacted with aliphatic hydrophobic residues, M177 (5.38) and V178 (5.39), through a hydrophobic interaction and were situated in proximity to F168 (EL2) F182 (5.43), consistent with the optimized binding affinity of compound **10**.

A comparison of the docking modes of Cl-IB-MECA and compound **10** in the putative binding domain showed considerable overlap of the ribose rings and of the adenine moieties, although in compound **10** both were situated a little closer to extracellular loop 2 (Figure 1B). Previously, it was noted that 5'-uronamide analogues, typically of derivatives having bulky N⁶-substituents, generally gain affinity in comparison to the corresponding 5'-hydroxyl analogue. Here, the 5'-uronamide analogue **19** (agonist) of the most potent 5'-hydroxyl analogue **10** (antagonist) displayed a lower binding affinity, which could be explained by the shift of the ribose position in adenosine analogue having a bulky 2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl) substituent in comparison to those having N⁶ bulky substituents. The binding of the cyclopentylmethyl group in **10** was directed more toward the upper part of TM5, partially overlapping with the binding site of the 3-iodophenyl ring in Cl-IB-MECA. Curiously, other closely related triazolo derivatives displayed a higher potency of the 5'-uronamide analogues; thus, compound **10** must bind to the receptor in a very distinct manner. There was a subtle difference in orientation between the 2-cyclopentyl group and bulkier groups like benzyl (**9**) or cyclohexylmethyl (**11**), which were associated with unfavorable van der Waals interactions and resulted in a decrease of binding affinity of 7- and 16-fold, respectively. In addition, the same preferred χ_1 angles of the energetically favorable bound conformation, common to Cl-IB-MECA and compound **10**, were consistent with the empirical finding that the combination of bulky N⁶ and C2 substituents was unfavorable for A₃AR selectivity because of competitive interaction of these bulky substituents. Thus, the modeling has demonstrated that the human A₃AR preference of 2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl) derivatives in the 5'-OH series might be explained by optimal van der Waals interactions.

Conclusions

Several 2-(1,2,3-triazol-1-yl)-N⁶-methyl-substituted adenosine derivatives described in the present study displayed A₃AR affinities in the low nanomolar range, showed very high A₃/A_{2A}, and a moderate to high A₃/A₁ selectivity. Contrary to what we expected, the 2-triazole analogues with an unmodified ribose moiety (**1–14**) showed antagonist or weak partial agonist activity at the A₃AR. A 2-(4-cyclopentylmethyl-(1,2,3-triazol-1-yl))-N⁶-methyl

derivative **10** was 260-fold selective in binding in comparison to the A₁AR. The binding of the 4-cyclopentylmethyl group in **10**, in distinction to the binding of closely related bulky groups pendent on the triazole ring, was directed more toward the upper part of TM5 partially overlapping with the binding site of the 3-iodophenyl ring in Cl-IB-MECA. The 5'-*N*-ethyluronamide modification was dominant over the efficacy reducing effects at the 2 position and was capable of fully re-establishing the A₃AR agonist activity, resulting in highly potent and selective A₃AR agonists **15–19**. The most selective agonist derivative was compound **17**, 9-(5-ethylcarbamoyl- β -D-ribofuranosyl)-*N*⁶-methyl-2-(4-pyridin-2-yl-1,2,3-triazol-1-yl)adenine, which was 910-fold selective in binding to the A₃AR in comparison to the A₁AR. The retention of high human A₃AR affinity in compound **20** was not typical of previous findings that double bulky substitution at the 2 and *N*⁶ positions tended to reduce A₃AR affinity markedly. Thus, the 2-triazol-1-yl-*N*⁶-methyladenosine analogues **1–11** constitute a novel class of highly potent and selective nucleoside-based A₃AR partial agonists and antagonists (all of which maintain an intact ribose in the molecular structure) and agonists. Since the reported analogues show excellent affinity for the A₃AR and span the full intrinsic activity range, they might be useful as pharmacological tools or as leads for further optimization.

Experimental Section

All reagents were from standard commercial sources and of analytic grade, except for the benzylic azides, which were prepared by treating the corresponding benzylic bromides with NaN₃ in DMF. Precoated Merck silica gel F254 plates were used for TLC, and spots were examined under UV light at 254 nm and further visualized by sulfuric acid–anisaldehyde spray. Column chromatography was performed on ICN silica gel (63–200 μ m, 60 Å, ICN Biochemicals, Eschwege, Germany). NMR spectra were obtained with a Varian Mercury 300 MHz spectrometer. Chemical shifts are given in ppm (δ) relative to the residual solvent signals, which in the case of DMSO-*d*₆ were 2.54 ppm for ¹H and 40.5 ppm for ¹³C. Structural assignment was confirmed with COSY and DEPT. All signals assigned to hydroxyl groups were exchangeable with D₂O. Exact mass measurements were performed on a quadrupole/orthogonal-acceleration time-of-flight (Q/oaTOF) tandem mass spectrometer (qToF 2, Micromass, Manchester, U.K.) equipped with a standard electrospray ionization (ESI) interface. Samples were infused in a 2-propanol/water (1:1) mixture at 3 μ L/min. For the compounds that precipitated from the reaction medium, the yields were calculated from the amount obtained after filtration and are lower than the actual yields, since in most cases a considerable amount remained in solution.

***N*⁶-Methyl-9-(β -D-ribofuranosyl)-2-(1,2,3-triazol-1-yl)adenine (1)**

In a pressure tube was added **23** (165 mg, 0.51 mmol), trimethylsilylacetylene (292 μ L, 2.05 mmol), and 4 mL of DMF. The mixture was stirred at 105 °C for 15 h. After solvent evaporation, the yellowish residue was dissolved in 2 mL of a 1.0 M solution of tetrabutylammonium fluoride in THF and stirred for 5 h. The reaction was monitored by NMR. After evaporation of the solvent, the residue was dissolved in ethyl acetate. Water was added, and the triazole product was precipitated in the water layer. After overnight cooling and filtration, the precipitate was further purified on a silica gel column (CH₂Cl₂/MeOH,

92:8) and yielded compound **1** as a white solid (82 mg, 46%). ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.06 (d, 3H, *J* = 4.5 Hz, *N*⁶-CH₃), 3.54–3.61 (m, 1H, H-5'A), 3.65–3.72 (m, 1H, H-5'B), 3.96 (dd, 1H, *J* = 3.8 and 7.9 Hz, H-4'), 4.20 (dd, 1H, *J* = 4.7 and 8.2 Hz, H-3'), 4.65 (app q, *J* = 5.9 Hz, H-2'), 4.98 (t, 1H, *J* = 5.6 Hz, 5'-OH), 5.23 (d, 1H, *J* = 5.0 Hz, 3'-OH), 5.48 (d, 1H, *J* = 6.2 Hz, 2'-OH), 5.95 (d, 1H, *J* = 5.9 Hz, H-1'), 7.92 (d, 1H, *J* = 1.2 Hz, H-4'), 8.37 (d, 1H, *J* = 4.6 Hz, *N*⁶-H), 8.46 (s, 1H, H-8), 8.82 (br s, 1H, H-5''). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 27.84 (*N*⁶-CH₃), 62.19 (C-5'), 71.13 (C-3'), 74.30 (C-2'), 86.42 (C-4'), 88.01 (C-1'), 119.75 (C-5), 124.67 (C-5''), 134.25 (C-4''), 141.13 (C-8), 149.56 and 149.85 (C-2 and C-4), 156.082 (C-6). HRMS (ESI-MS) C₁₃H₁₇N₈O₄ [M + H]⁺: 349.1367 found; 349.1372 calcd. Anal. (C₁₃H₁₆N₈O₄·½H₂O) C, H, N.

2-(4-Ethyl-1,2,3-triazol-1-yl)-*N*⁶-methyl-9-(β-D-ribofuranosyl)-adenine (**2**)

Compound **23** (70 mg, 0.217 mmol), sodium ascorbate (8.6 mg, 0.043 mmol), and CuSO₄·5H₂O (2.2 mg, 0.009 mmol) were suspended in 20 mL of H₂O/BuOH (3:1). The mixture was saturated with 1-butyne and stirred for 4 days at room temperature in a Parr apparatus. Purification on a preparative TLC plate (CH₂Cl₂/MeOH, 90:10) resulted in compound **2** as a white solid in 40% yield. ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.27 (t, 3H, *J* = 7.62 Hz, CH₃), 2.75 (q, 2H, *J* = 7.6 Hz, CH₂), 3.05 (d, 3H, *J* = 4.4 Hz, *N*⁶-CH₃), 3.51–3.59 (m, 1H, H-5'A), 3.61–3.70 (m, 1H, H-5'B), 3.94 (dd, 1H, *J* = 4.0 and 7.6 Hz, H-4'), 4.15 (dd, 1H, *J* = 4.4 and 7.9 Hz, H-3'), 4.60 (app q, *J* = 5.6 Hz, H-2'), 4.97 (t, 1H, *J* = 5.6 Hz, 5'-OH), 5.22 (d, 1H, *J* = 4.7 Hz, 3'-OH), 5.47 (d, 1H, *J* = 6.2 Hz, 2'-OH), 5.93 (d, 1H, *J* = 6.2 Hz, H-1'), 8.34 (d, 1H, *J* = 4.4 Hz, *N*⁶-H), 8.45 (s, 1H, H-8), 8.55 (s, 1H, H-5''). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 14.32 (CH₃), 19.08 (CH₂), 27.84 (*N*⁶-CH₃), 62.13 (C-5'), 71.15 (C-3'), 74.34 (C-2'), 86.43 (C-4'), 87.84 (C-1'), 119.57 (C-5), 120.962 (C-5''), 140.92 (C-8), 149.31, 149.63, 149.88 (C-2, C-4, and C-4''), 156.05 (C-6). HRMS (ESI-MS) C₁₅H₂₁N₈O₄ [M + H]⁺: 377.1682 found; 377.1685 calcd. Anal. (C₁₅H₂₀N₈O₄) C, H, N.

General Procedure for the Synthesis of 4''-Substituted 2-(1,2,3-Triazol-1-yl)adenosine Derivatives 3–11

Compound **23** (70 mg, 0.217 mmol), sodium ascorbate (8.6 mg, 0.043 mmol), and CuSO₄·5H₂O (2.2 mg, 0.009 mmol) were suspended in 2 mL of H₂O/BuOH (3:1). The appropriate alkyne (2 equiv) was subsequently added, and the mixture was stirred overnight at room temperature. The 2-triazol-1-yl compounds (generally) precipitated from this reaction medium and were isolated by filtration with water.

2-(4-Butyl-1,2,3-triazol-1-yl)-*N*⁶-methyl-9-(β-D-ribofuranosyl)-adenine (**3**)

The reaction of **23** (70 mg, 0.217 mmol) with 1-hexyne (50 μL, 0.435 mmol) gave compound **3** in 59% yield. ¹H NMR (300 MHz, DMSO-*d*₆): δ 0.93 (t, 3H, *J* = 7.3 Hz, CH₃), 1.38 (m, 2H, CH₂), 1.66 (m, 2H, CH₂), 2.71 (t, 2H, *J* = 7.2 Hz, C4''-CH₂), 3.05 (d, 3H, *J* = 4.0 Hz, *N*⁶-CH₃), 3.52–3.62 (m, 1H, H-5'A), 3.62–3.72 (m, 1H, H-5'B), 3.95 (dd, 1H, *J* = 3.6 and 7.2 Hz, H-4'), 4.18 (dd, 1H, *J* = 4.8 and 8.1 Hz, H-3'), 4.62 (app q, 1H, *J* = 5.7 Hz, H-2'), 5.01 (t, 1H, *J* = 5.2 Hz, 5'-OH), 5.29 (d, 1H, *J* = 4.0 Hz, 3'-OH), 5.54 (d, 1H, *J* = 5.6 Hz, 2'-OH), 5.94 (d, 1H, *J* = 5.9 Hz, H-1'), 8.36 (d, 1H, *J* = 4.1 Hz, *N*⁶-H), 8.45 (s, 1H, H-8), 8.56 (s, 1H, H-5''). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 14.37 (CH₃), 22.37 (CH₂), 25.21

(CH₂), 27.83 (N⁶-CH₃), 31.68 (CH₂), 62.14 (C-5'), 71.15 (C-3'), 74.36 (C-2'), 86.43 (C-4'), 87.88 (C-1'), 119.56 (C-5), 121.33 (C-5''), 140.96 (C-8), 147.88 and 149.90 (C-2, C-4 and C-4''), 156.07 (C-6). HRMS (ESI-MS) C₁₇H₂₅N₈O₄ [M + H]⁺: 405.1992 found, 405.1998 calcd. Anal. (C₁₇H₂₄N₈O₄) C, H, N.

2-[4-(2-Hydroxyethyl)-1,2,3-triazol-1-yl]-N⁶-methyl-9-(β-D-ribofuranosyl) adenine (4)

The reaction of **23** (70 mg, 0.217 mmol) with 3-butyn-1-ol (33 μL, 0.435 mmol) afforded compound **4** without precipitation. After solvent evaporation, the mixture was purified on a silica gel column (90:10 CH₂Cl₂/MeOH + 1% 7 N NH₃ in MeOH), yielding compound **11** as a white solid in 68% yield. ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.85 (t, 2H, *J* = 6.9 Hz, CH₂), 3.03 (d, 3H, *J* = 4.7 Hz, N⁶-CH₃), 3.52–3.59 (m, 1H, H-5'A), 3.63–3.72 (m, 3H, H-5'B and CH₂), 3.94 (dd, 1H, *J* = 3.5 and 7.3 Hz, H-4'), 4.16 (dd, 1H, *J* = 4.8 and 8.1 Hz, H-3'), 4.59 (app q, 1H, *J* = 5.4 Hz, H-2'), 4.74 (t, 1H, *J* = 5.8 Hz, CH₂-OH), 4.97 (app t, 1H, *J* = 5.6 Hz, 5'-OH), 5.24 (d, 1H, *J* = 5.0 Hz, 3'-OH), 5.50 (d, 1H, *J* = 6.2 Hz, 2'-OH), 5.93 (d, 1H, *J* = 6.2 Hz, H-1'), 8.31 (d, 1H, *J* = 4.7 Hz, N⁶-H), 8.43 (s, 1H, H-8), 8.54 (s, 1H, H-5'). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 27.83 (N⁶-CH₃), 29.70 (CH₂), 60.85 (CH₂-OH), 62.13 (C-5'), 71.15 (C-3'), 74.35 (C-2'), 86.43 (C-4'), 87.81 (C-1'), 119.56 (C-5), 122.02 (C-5''), 140.49 (C-8), 145.49, 149.88, and 149.65 (C-2, C-4, and C-4''), 156.05 (C-6). HRMS (ESI-MS) C₁₅H₂₁N₈O₅ [M + H]⁺: 393.1630 found, 393.1634 calcd. Anal. (C₁₅H₂₀N₈O₅·H₂O) C, H, N.

2-(4-Dimethylaminomethyl-1,2,3-triazol-1-yl)-N⁶-methyl-9-(β-D-ribofuranosyl)adenine (5)

The reaction of **23** (70 mg, 0.217 mmol) with 1-dimethylamino-2-propyne (47 μL, 0.435 mmol) gave compound **5** without precipitation. The volatiles were removed under reduced pressure, and the residue was purified on a silica gel column (80:20 CH₂Cl₂/MeOH + 1% 7 N NH₃ in MeOH). Compound **5** was obtained as a white solid in 67% yield. ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.20 (s, 6H, 2 × CH₃), 3.05 (d, 3H, *J* = 4.4 Hz, N⁶-CH₃), 3.54–3.62 (m, 3H, H-5'A and CH₂), 3.65–3.72 (m, 1H, H-5'B), 3.95 (dd, 1H, *J* = 4.1 and 7.6 Hz, H-4'), 4.18 (dd, 1H, *J* = 5.0 and 8.2 Hz, H-3'), 4.62 (app q, 1H, *J* = 5.4 Hz, H-2'), 4.98 (t, 1H, *J* = 5.6 Hz, 5'-OH), 5.23 (d, 1H, *J* = 5.0 Hz, 3'-OH), 5.49 (d, 1H, *J* = 6.2 Hz, 2'-OH), 5.95 (d, 1H, *J* = 6.2 Hz, H-1'), 8.38 (d, 1H, *J* = 4.4 Hz, N⁶-H), 8.45 (s, 1H, H-8), 8.64 (s, 1H, H-5'). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 27.85 (N⁶-CH₃), 45.18 (N(CH₃)₂), 53.85 (CH₂), 62.10 (C-5'), 71.12 (C-3'), 74.38 (C-2'), 86.41 (C-4'), 87.84 (C-1'), 119.64 (C-5), 123.328 (C-5''), 140.97 (C-8), 144.41, 149.59, 149.79 (C-2, C-4, and C-4''), 156.05 (C-6). HRMS (ESI-MS) C₁₆H₂₄N₉O₄ [M + H]⁺: 406.1944 found, 406.1951 calcd. Anal. (C₁₆H₂₃N₉O₄) C, H, N. N calcd, 31.09; found, 30.41.

N⁶-Methyl-2-(4-phenyl-1,2,3-triazol-1-yl)-9-(β-D-ribofuranosyl) adenine (6)

The reaction of **23** (70 mg, 0.217 mmol) with phenylacetylene (48 μL, 0.435 mmol) yielded compound **6** (54%) as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.11 (d, 3H, *J* = 4.5 Hz, N⁶-CH₃), 3.55–3.63 (m, 1H, H-5'A), 3.67–3.74 (m, 1H, H-5'B), 3.97 (dd, *J* = 3.6 and 7.2 Hz, H-4'), 4.21 (dd, *J* = 4.8 and 8.1 Hz, H-3'), 4.66 (app q, *J* = 5.4 Hz, H-2'), 5.03 (app t, 1H, *J* = 5.6 Hz, 5'-OH), 5.29 (d, 1H, *J* = 5.0 Hz, 3'-OH), 5.54 (d, 1H, *J* = 6.2 Hz, 2'-OH), 5.99 (d, 1H, *J* = 5.9 Hz, H-1'), 7.4 (t, 1H, *J* = 7.3 Hz, Ph), 7.50 (t, 2H, *J* = 7.5 Hz, Ph), 8.06

(d, 2H, $J = 7.3$ Hz, Ph), 8.44 (d, 1H, $J = 4.5$ Hz, N^6 -H), 8.49 (s, 1H, H-8), 9.31 (s, 1H, H-5'). ^{13}C NMR (300 MHz, DMSO- d_6): δ 27.92 (N^6 -CH $_3$), 62.16 (C-5'), 71.17 (C-3'), 74.39 (C-2'), 86.48 (C-4'), 87.94 (C-1'), 119.85 (C-5), 120.68 (C-5''), 126.27, 128.95, 129.61, and 130.85 (Ph), 141.082 (C-8), 147.02 and 149.77 (C-2, C-4, and C-4''), 156.10 (C-6). HRMS (ESI-MS) $\text{C}_{19}\text{H}_{21}\text{N}_8\text{O}_4$ $[\text{M} + \text{H}]^+$: 425.1689 found, 425.1685 calcd. Anal. ($\text{C}_{19}\text{H}_{20}\text{N}_8\text{O}_4$) C, H, N.

N^6 -Methyl-2-[4-pyridin-2-yl-1,2,3-triazol-1-yl]-9-(β -D-ribofuranosyl) adenine (7)

The reaction of **23** (70 mg, 0.217 mmol) with 2-ethynylpyridine (44 μL , 0.435 mmol) afforded compound **7** as a white solid in 55% yield. ^1H NMR (300 MHz, DMSO- d_6): δ 3.09 (d, 3H, $J = 4.1$ Hz, N^6 -CH $_3$), 3.57–3.66 (m, 1H, H-5'A), 3.67–3.76 (m, 1H, H-5'B), 3.97 (dd, 1H, $J = 3.9$ and 7.5 Hz, H-4'), 4.19 (dd, 1H, $J = 4.8$ and 8.1 Hz, H-3'), 4.64 (app q, 1H, $J = 6.0$ Hz, H-2'), 4.99 (t, 1H, $J = 5.6$ Hz, 5'-OH), 5.26 (d, 1H, $J = 5.0$ Hz, 3'-OH), 5.54 (d, 1H, $J = 6.2$ Hz, 2'-OH), 5.99 (d, 1H, $J = 5.9$ Hz, H-1'), 7.42 (m, 1H, pyridin-2-yl), 7.96 (m, 1H, pyridin-2-yl), 8.16 (d, 1H, $J = 7.3$ Hz, pyridin-2-yl), 8.42 (d, 1H, $J = 4.1$ Hz, 1H, N^6 -H), 8.49 (s, 1H, H-8), 8.68 (d, 1H, $J = 4.1$ Hz, pyridin-2-yl), 9.16 (s, 1H, H-5''). ^{13}C NMR (300 MHz, DMSO- d_6): δ 27.92 (N^6 -CH $_3$), 62.13 (C-5'), 71.14 (C-3'), 74.49 (C-2'), 86.47 (C-4'), 88.16 (C-1'), 119.92 (C-5), 120.53 (C-5''), 121.07 (pyridin-2-yl), 122.25 (pyridin-2-yl), 137.79 (pyridin-2-yl), 141.28 (C-8), 148.47, 150.45 and 150.56 (C-2, C-4, C-4'', and pyridin-2-yl), 156.28 (C-6). HRMS (ESI-MS) $\text{C}_{18}\text{H}_{19}\text{N}_9\text{O}_4\text{Na}$ $[\text{M} + \text{Na}]^+$: 448.1458 found, 448.1457 calcd. Anal. ($\text{C}_{18}\text{H}_{19}\text{N}_9\text{O}_4$) C, H, N.

N^6 -Methyl-2-[4-(4-propoxyphenyl)-1,2,3-triazol-1-yl]-9-(β -D-ribofuranosyl) adenine (8)

The reaction of **23** (70 mg, 0.217 mmol) with 1-eth-1-ynyl-4-propoxybenzene (57 μL , 0.435 mmol) afforded compound **8** as a white solid in 36% yield. ^1H NMR (300 MHz, DMSO- d_6): δ 0.99 (t, 3H, $J = 7.3$ Hz, CH $_3$), 1.71–1.78 (m, 2H, CH $_2$), 3.10 (d, 3H, $J = 4.1$ Hz, N^6 -CH $_3$), 3.54–3.62 (m, 1H, H-5'A), 3.64–3.72 (m, 1H, H-5'B), 3.98 (m, 3H, H-4' and CH $_2$), 4.18 (dd, 1H, $J = 4.8$ and 8.1 Hz, H-3'), 4.64 (app q, 1H, $J = 5.4$ Hz, H-2'), 4.99 (t, 1H, $J = 5, 7$ Hz, 5'-OH), 5.25 (d, 1H, $J = 4.1$ Hz, 3'-OH), 5.50 (d, 1H, $J = 5.9$ Hz, 2'-OH), 5.97 (d, 1H, $J = 6.2$ Hz, H-1'), 7.03 (d, 2H, $J = 8.8$ Hz, Ph), 7.94 (d, 2H, $J = 8.8$ Hz, Ph), 8.36 (d, 1H, $J = 4.1$ Hz, 1H, N^6 -H), 8.45 (s, 1H, H-8), 9.15 (s, 1H, H-5''). ^{13}C NMR (300 MHz, DMSO- d_6): δ 11.08 (CH $_3$), 22.73 (CH $_2$), 27.90 (N^6 -CH $_3$), 62.16 (C-5'), 69.71 (OCH $_2$), 71.18 (C-3'), 74.38 (C-2'), 86.46 (C-4'), 87.91 (C-1'), 115.50 (Ph), 119.60 (C-5), 123.28 (C-5''), 127.66 (Ph), 140.01 (C-8), 147.01, 149.82, 150.45 (C-4, C-2, and C-4''), 156.10 (C-6). HRMS (ESI-MS) $\text{C}_{22}\text{H}_{27}\text{N}_8\text{O}_5$ $[\text{M} + \text{H}]^+$: 483.2109 found, 483.2104 calcd. Anal. ($\text{C}_{22}\text{H}_{26}\text{N}_8\text{O}_5$) C, H, N.

N^6 -Methyl-2-(4-benzyl-1,2,3-triazol-1-yl)-9-(β -D-ribofuranosyl) adenine (9)

The reaction of **23** (70 mg, 0.217 mmol) with 3-phenyl-1-propyne (54 μL , 0.435 mmol) gave compound **9** as a white solid in 43% yield. ^1H NMR (300 MHz, DMSO- d_6): δ 3.03 (d, 3H, $J = 3.8$ Hz, N^6 -CH $_3$), 3.53–3.62 (m, 1H, H-5'A), 3.64–3.71 (m, 1H, H-5'B), 3.95 (dd, 1H, $J = 3.7$ and 7.2 Hz, H-4'), 4.11 (s, 2H, CH $_2$), 4.17 (dd, 1H, $J = 4.8$ and 8.1 Hz, H-3'), 4.61 (app q, 1H, $J = 5.7$ Hz, H-2'), 4.97 (app t, 1H, $J = 5.3$ Hz, 5'-OH), 5.22 (d, 1H, $J = 4.7$ Hz, 3'-OH), 5.47 (d, 1H, $J = 5.9$ Hz, 2'-OH), 5.94 (d, 1H, $J = 5.9$ Hz, H-1'), 7.23 (m, 1H, Ph), 7.32 (d, 4H, $J = 4.4$ Hz, Ph), 8.34 (d, 1H, $J = 3.8$ Hz, N^6 -H), 8.45 (s, 1H, H-8), 8.59 (s, 1H, H-5')

′). ^{13}C NMR (300 MHz, DMSO- d_6): δ 25.32 (N^6 -CH₃), 32.51 (CH₂), 62.11 (C-5′), 71.13 (C-3′), 74.43 (C-2′), 86.41 (C-4′), 87.96 (C-1′), 121.42 (C-5), 121.97 (C-5′′), 126.91, 129.12, 129.21, and 140.02 (Ph), 140.88 (C-8), 147.42, 149.58, and 149.81 (C-4, C-2, and C-4′′), 156.09 (C-6). HRMS (ESI-MS) C₂₀H₂₃N₈O₄ [M + H]⁺: 439.1846 found, 439.1842 calcd. Anal. (C₂₀H₂₂N₈O₄) C, H, N.

2-(4-Cyclopentylmethyl-1,2,3-triazol-1-yl)- N^6 -methyl-9-(β -D-ribofuranosyl) adenine (10)

The reaction of **23** (70 mg, 0.217 mmol) with 3-cyclopentyl-1-propyne (57 μL , 0.435 mmol) yielded compound **10** (32%) as a white solid. ^1H NMR (300 MHz, DMSO- d_6): δ 1.23–1.28 (m, 2H, cyclopentyl), 1.48–1.62 (m, 4H, cyclopentyl), 1.71–1.75 (m, 2H, cyclopentyl), 2.19–2.25 (m, 1H, cyclopentyl), 2.72 (d, 2H, J = 7.3 Hz, CH₂-cyclopentyl), 3.05 (d, 3H, J = 3.9 Hz, N^6 -CH₃), 3.53–3.61 (m, 1H, H-5′A), 3.63–3.72 (m, 1H, H-5′B), 3.96 (dd, 1H, J = 3.6 and 7.2 Hz, H-4′), 4.19 (dd, 1H, J = 4.8 and 8.1 Hz, H-3′), 4.62 (app q, 1H, J = 5.9 Hz, H-2′), 4.98 (t, 1H, J = 5.3 Hz, 5′-OH), 5.23 (d, 1H, J = 4.7 Hz, 3′-OH), 5.49 (d, 1H, J = 6.5 Hz, 2′-OH), 5.95 (d, 1H, J = 5.9 Hz, H-1′), 8.34 (d, 1H, J = 3.9 Hz, N^6 -H), 8.45 (s, 1H, H-8), 8.55 (s, 1H, H-5′′). ^{13}C NMR (300 MHz, DMSO- d_6): δ 25.37 (cyclopentyl), 27.83 (N^6 -CH₃), 31.56 (CH₂), 32.55 (cyclopentyl), 62.15 (C-5′), 71.15 (C-3′), 74.34 (C-2′), 86.43 (C-4′), 87.87 (C-1′), 119.60 (C-5), 121.58 (C-5′′), 140.92 (C-8), 147.33, 149.89 (C-4, C-2, and C4′′), 156.07 (C-6). HRMS (ESI-MS) C₁₉H₂₇N₈O₄ [M + H]⁺: 431.2153 found, 431.2155 calcd. Anal. (C₁₉H₂₆N₈O₄) C, H, N.

2-(4-Cyclohexylmethyl-1,2,3-triazol-1-yl)- N^6 -methyl-9-(β -D-ribofuranosyl) adenine (11)

The reaction of **23** (70 mg, 0.217 mmol) with cyclohexyl-1-propyne (63 μL , 0.435 mmol) gave compound **11** in 82% yield. ^1H NMR (300 MHz, DMSO- d_6): δ 0.86–1.28 (br m, 6H, cyclohexyl), 1.54–1.72 (br m, 5H, cyclohexyl), 2.58 (d, 2H, J = 6.9 Hz, CH₂), 3.03 (d, 3H, J = 3.9 Hz, N^6 -CH₃), 3.51–3.59 (m, 1H, H-5′A), 3.63–3.70 (m, 1H, H-5′B), 3.94 (dd, 1H, J = 4.2 and 7.5 Hz, H-4′), 4.16 (dd, 1H, J = 4.8 and 8.1 Hz, H-3′), 4.59 (app q, 1H, J = 6.3 Hz, H-2′), 4.97 (t, 1H, J = 5.5 Hz, 5′-OH), 5.22 (d, 1H, J = 4.8 Hz, 3′-OH), 5.47 (d, 1H, J = 6.3 Hz, 2′-OH), 5.93 (d, 1H, J = 6.0 Hz, H-1′), 8.30 (d, 1H, J = 3.9 Hz, N^6 -H), 8.43 (s, 1H, H-8), 8.51 (s, 1H, H-5′′). ^{13}C NMR (300 MHz, DMSO- d_6): δ 26.31 (cyclohexyl), 26.66 (cyclohexyl), 27.84 (N^6 -CH₃), 33.16 (cyclohexyl), 38.22 (CH₂), 62.14 (C-5′), 71.15 (C-3′), 74.35 (C-2′), 86.44 (C-4′), 87.86 (C-1′), 119.60 (C-5), 121.93 (C-5′′), 140.92 (C-8), 146.45, 149.92 (C-4, C-2, and C-4′′), 153.51 (C-6). HRMS (ESI-MS) C₂₀H₂₉N₈O₄ [M + H]⁺: 445.2305 found, 445.2311 calcd. Anal. (C₂₀H₂₈N₈O₄) C, H, N.

General Procedure for the Synthesis of 4′′-Substituted 2-(1,2,3-Triazol-4-yl)adenosine Derivatives 12–14

Compound **25** (100 mg, 0.32 mmol), sodium ascorbate (13 mg, 0.06 mmol), and CuSO₄·5H₂O (3 mg, 0.013 mmol) were suspended in 30 mL of H₂O/BuOH (3:1). The appropriate azide (2 equiv) was subsequently added, and the mixture was stirred overnight at room temperature. The 2-triazol-4-yl compounds (generally) precipitated from this reaction medium and were isolated by filtration with water.

2-(1-Benzyl-1,2,3-triazol-4-yl)-N⁶-methyl-9-(β-D-ribofuranosyl) adenine (12)

The reaction of **25** (100 mg, 0.32 mmol) with 85 mg (0.64 mmol) of benzylazide gave compound **12** in 78% yield (110 mg). ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.03 (br s, 3H, N⁶-CH₃), 3.52–3.58 (m, 1H, H-5'A), 3.60–3.66 (m, 1H, H-5'B), 3.92 (app d, H-4', *J* = 2.9 Hz, H-4'), 4.15 (dd, 1H, *J* = 4.7 and 7.6 Hz, H-3'), 4.60 (app q, 1H, *J* = 5.9 Hz, H-2'), 5.08 (t, 1H, *J* = 5.4 Hz, 5'-OH), 5.19 (d, 1H, *J* = 3.5 Hz, 3'-OH), 5.44 (d, 1H, *J* = 5.6 Hz, 2'-OH), 5.68 (s, 2H, CH₂), 5.97 (d, 6.2 Hz, H-1'), 7.38 (br s, 5H, Ph), 7.82 (br s, 1H, N⁶-H), 8.36 (s, 1H, H-8), 8.66 (s, 1H, H-5''). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 27.54 (N⁶-CH₃), 53.62 (CH₂), 62.29 (C-5'), 71.30 (C-3'), 74.30 (C-2'), 86.41 (C-4'), 87.77 (C-1'), 119.52 (C-5), 126.41 (C-5''), 128.63, 128.86, 129.48 and 136.71 (Ph), 140.27 (C-8), 148.22, 153.56, 153.72 (C-2, C-4, and C-4'), 155.69 (C-6). HRMS (ESI-MS) C₂₀H₂₃N₈O₄ [M + H]⁺: 439.1834 found, 439.1842 calcd. Anal. (C₂₀H₂₂N₈O₄) C, H, N.

2-[1-(3-Methoxybenzyl)-1,2,3-triazol-4-yl]-N⁶-methyl-9-(β-D-ribofuranosyl) adenine (13)

The reaction of **25** (100 mg, 0.32 mmol) with 104 mg (0.64 mmol) of 3-methoxybenzylazide gave compound **13** in 80% yield (120 mg). ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.03 (br s, 3H, N⁶-CH₃), 3.52–3.60 (m, 1H, H-5'A), 3.64–3.72 (m, 1H, H-5'B), 3.95 (app d, H-4', *J* = 2.9 Hz, H-4'), 4.15 (dd, 1H, *J* = 4.7 and 7.6 Hz, H-3'), 4.60 (app q, 1H, *J* = 6.4 Hz, H-2'), 5.07 (t, 1H, *J* = 5.1 Hz, 5'-OH), 5.21 (d, 1H, *J* = 4.2 Hz, 3'-OH), 5.46 (d, 1H, *J* = 6.3 Hz, 2'-OH), 5.62 (s, 2H, CH₂), 5.95 (d, 1H, *J* = 6.6 Hz, H-1'), 6.91 (m, 3H, Ph), 7.29 (t, 1H, *J* = 7.9 Hz, Ph), 7.79 (br s, 1H, N⁶-H), 8.34 (s, 1H, H-8), 8.63 (s, 1H, H-5''). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 27.59 (N⁶-CH₃), 53.45 (CH₂), 55.82 (OCH₃), 62.30 (C-5'), 71.33 (C-3'), 74.25 (C-2'), 86.42 (C-4'), 87.70 (C-1'), 114.44 and 114.20 (Ph), 119.51 (C-5), 120.72 (Ph), 130.65 (C-5''), 138.21 (C-8), 148.22, 153.56, 153.64 (C-2, C-4, and C-4'), 155.69 (C-6), 160.14 (Ph). HRMS (ESI-MS) C₂₁H₂₅N₈O₅ [M + H]⁺: 469.1938 found, 469.1947 calcd. Anal. (C₂₁H₂₄N₈O₅) C, H, N.

2-[1-(3-Chlorobenzyl)-1,2,3-triazol-4-yl]-N⁶-methyl-9-(β-D-ribofuranosyl) adenine (14)

The reaction of **25** (100 mg, 0.32 mmol) with 107 mg (0.64 mmol) of 3-chlorobenzylazide gave compound **14** in 73% yield (110 mg). ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.04 (br s, 3H, N⁶-CH₃), 3.53–3.60 (m, 1H, H-5'A), 3.64–3.71 (m, 1H, H-5'B), 3.96 (app d, H-4', *J* = 2.9 Hz, H-4'), 4.17 (dd, 1H, *J* = 4.7 and 7.6 Hz, H-3'), 4.64 (app q, 1H, *J* = 5.8 Hz, H-2'), 5.09 (t, 1H, *J* = 5.3 Hz, 5'-OH), 5.20 (d, 1H, *J* = 4.4 Hz, 3'-OH), 5.45 (d, 1H, *J* = 6.2 Hz, 2'-OH), 5.97 (d, 1H, *J* = 6.2 Hz, H-1'), 7.31–7.36 (m, 1H, Ph), 4.41–7.47 (m, 3H, Ph), 7.83 (br s, 1H, N⁶-H), 8.37 (s, 1H, H-8), 8.72 (s, 1H, H-5''). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 27.54 (N⁶-CH₃), 52.80 (CH₂), 62.31 (C-5'), 71.33 (C-3'), 74.27 (C-2'), 86.43 (C-4'), 87.69 (C-1'), 119.56 (C-5), 126.63 (C-5''), 127.53, 128.53, 128.84, 131.42, 133.98, and 139.15 (Ph), 140.36 (C-8), 148.22, 150.03, and 153.43 (C-2, C-4, and C-4'), 155.78 (C-6). HRMS (ESI-MS) C₂₀H₂₂N₈O₄Cl [M + H]⁺: 473.1452 found, 473.1452 calcd. Anal. (C₂₀H₂₁N₈O₄Cl) C, H, N.

9-(5-Ethylcarbamoyl-β-D-ribofuranosyl)-N⁶-methyl-2-(1,2,3-triazol-1-yl)adenine (15)

In a pressure tube was added **31** (110 mg, 0.30 mmol), trimethylsilylacetylene (259 μL, 1.81 mmol), and 4 mL of DMF. The mixture was stirred at 105 °C for 15 h. Solvent evaporation

yielded a yellowish solid that was dissolved 6 mL of a 1.0 solution of tetrabutylammonium fluoride in THF and stirred for 5 h. After solvent evaporation, the residue was dissolved in ethyl acetate. Water was added, and the triazole precipitated in the water layer. After overnight cooling and filtration, the precipitate was further purified on a silica gel column (CH₂Cl₂/MeOH, 93:7) and yielded compound **15** as a white solid (49 mg, 42%). ¹H NMR (300 MHz, DMSO-*d*₆): δ 0.90 (t, 3H, CH₃), 3.05–3.21 (m, 2H, *N*-CH₂), 3.05 (d, 3H, *J* = 4.2 Hz, *N*⁶-CH₃), 4.26 (m, 1H, H-3'), 4.33 (d, 1H, *J* = 2.1 Hz, H-4'), 5.61 (d, 1H, *J* = 6.2 Hz, 3'-OH), 5.71 (d, 1H, *J* = 4.7 Hz, 2'-OH), 6.04 (d, 1H, *J* = 7.2 Hz, H-1'), 7.91 (d, 1H, *J* = 1.2 Hz, H-4''), 8.07 (t, 1H, *J* = 5.3 Hz, MHCO), 8.41 (d, 1H, *J* = 4.2 Hz, *N*⁶-H), 8.54 (s, 1H, H-8), 8.82 (br s, 1H, H-5''). ¹³CMR (300 MHz, DMSO-*d*₆): δ 15.16 (CH₃), 27.85 (*N*⁶-CH₃), 34.07 (CH₂), 73.64 (C-2' and C-3'), 84.98 (C-4'), 88.02 (C-1'), 119.91 (C-5), 124.70 (C-5''), 134.29 (C-4''), 141.59 (C-8), 149.69 and 149.90 (C-2 and C-4), 156.14 (C-6), 169.73 (C=O). HRMS (ESI-MS) C₁₅H₂₀N₉O₄ [M + H]⁺: 390.1676 found, 390.1683 calcd. Anal. (C₁₅H₁₉N₉O₄) C, H, N.

General Procedure for the Synthesis of 4''-Substituted 2-(1,2,3-Triazol-1-yl)adenosine Derivatives 16–18

To a mixture of **31** (100 mg, 0.28 mmol), CuI (5 mg, 0.03 mmol), and triethylamine (40 μL, 0.28 mmol) in water/acetonitrile (1:1), the appropriate alkyne (2 equiv) was added. The mixture was stirred for 5 days at room temperature. The reaction was monitored by ¹H NMR. The product was precipitated with water and cooled overnight. After filtration, the yellowish solid was purified on a silica gel column (CH₂Cl₂/MeOH, 90:10) to obtain the 1,2,3-triazol-1-yladenosine derivative as a white solid.

2-(4-Butyl-1,2,3-triazol-1-yl)-9-(5-ethylcarbamoyl-β-D-ribofuranosyl)-*N*⁶-methyladenine (**16**)

The reaction of compound **31** (100 mg, 0.28 mmol) with 1-hexyne (64 μL, 0.56 mmol) gave 65 mg (53%) of compound **16** as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆) δ 0.88–0.95 (m, 6H, 2 × CH₃), 1.31–1.43 (m, 2H, CH₂), 1.61–1.71 (m, 2H, CH₂), 2.72 (t, 2H, *J* = 7.8 Hz, C4''-CH₂), 3.05–3.22 (m, 2H, *N*-CH₂), 3.05 (d, 3H, *J* = 4.1 Hz, *N*⁶-CH₃), 4.25 (m, 1H, H-3'), 4.33 (d, 1H, *J* = 2.1 Hz, H-4'), 4.73 (m, 1H, H-2'), 5.59 (d, 1H, *J* = 6.3 Hz, 3'-OH), 5.69 (d, 1H, *J* = 4.5 Hz, 2'-OH), 6.04 (d, 1H, *J* = 6.9 Hz, H-1'), 8.09 (t, 1H, *J* = 5.4 Hz), 8.37 (d, 1H, *J* = 4.1 Hz, *N*⁶-H), 8.53 (s, 1H, H-8), 8.56 (s, 1H, H-5''). ¹³C NMR (300 MHz, DMSO-*d*₆): 14.36 (CH₃), 15.17 (CH₃), 22.35 (CH₂), 25.21 (CH₂), 27.84 (*N*⁶-CH₃), 31.70 (CH₂), 34.07 (CH₂), 73.60 and 73.64 (C-2' and C-3'), 84.99 (C-4''), 87.91 (C-1'), 119.79 (C-5), 121.45 (C-5''), 141.49 (C-8), 147.97, 149.72, and 149.93 (C-2, C-4, and C-4''), 156.11 (C-6), 169.73 (C=O). HRMS (ESI-MS) C₁₉H₂₈N₉O₄ [M + H]⁺: 446.2256 found, 446.2264 calcd. Anal. (C₁₉H₂₇N₉O₄) C, H, N.

9-(5-Ethylcarbamoyl-β-D-ribofuranosyl)-*N*⁶-methyl-2-(4-pyridin-2-yl-1,2,3-triazol-1-yl)adenine (**17**)

The reaction of compound **31** (50 mg, 0.14 mmol) with 2-ethynylpyridine (56 μL, 0.56 mmol) gave 35 mg (54%) of compound **17** as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 0.93 (t, 3H, *J* = 7.2 Hz, CH₃), 3.09–3.21 (m, 2H, *N*-CH₂), 3.10 (d, 3H, *J* = 4.2 Hz, *N*⁶-CH₃), 4.25 (m, 1H, H-3'), 4.35 (d, 1H, *J* = 2.1 Hz, H-4'), 4.74 (m, 1H, H-2'), 5.68 (d, 1H, *J* =

6.6 Hz, 2'-OH), 5.75 (d, 1H, $J = 4.5$ Hz, 3'-OH), 6.08 (d, 1H, $J = 6.6$ Hz, H-1'), 7.41 (m, 1H, pyridin-2-yl), 7.96 (m, 1H, pyridin-2-yl), 8.10 (t, 1H, $J = 6.0$ Hz, NHCO), 8.16 (d, 1H, $J = 8.1$ Hz, pyridin-2-yl), 8.48 (d, 1H, $J = 4.1$ Hz, 1H, N^6 -H), 8.60 (s, 1H, H-8), 8.67 (d, H, $J = 5.1$ Hz, pyridin-2-yl), 9.17 (s, 1H, H-5''). ^{13}C NMR (300 MHz, DMSO- d_6): δ 15.18 (CH₃), 27.94 (N^6 -CH₃), 34.11 (N -CH₂), 73.69 and 73.78 (C-2' and C-3'), 84.95 (C-4'), 87.98 (C-1'), 120.04 (C-5), 120.65 (C-5''), 122.20 and 124.11 (pyridin-2-yl), 138.027 (pyridin-2-yl), 141.64 (C-8), 147.95, 149.64, 149.67, and 149.98 (C-2, C-4, C-4'', and pyridin-2-yl), 150.49 (pyridin-2-yl), 156.13 (C-6), 169.76 (C=O). HRMS (ESI-MS) C₂₀H₂₃N₁₀O₄ [M + H]⁺: 467.1899 found, 467.1903 calcd. Anal. (C₂₀H₂₂N₁₀O₄) C, H, N. N calcd, 30.03; found, 29.55.

9-(5-Ethylcarbamoyl- β -D-ribofuranosyl)- N^6 -methyl-2-(4-benzyl-1,2,3-triazol-1-yl)adenine (18)

The reaction of compound **31** (70 mg, 0.19 mmol) with 3-phenyl-1-propyne (49 μL , 0.56 mmol) gave 35 mg (38%) of compound **18** as a white solid. ^1H NMR (300 MHz, DMSO- d_6): δ 0.87 (t, 3H, $J = 7.5$ Hz, CH₃), 3.03–3.20 (m, 2H, N -CH₂), 3.03 (d, 3H, 4.5 Hz, N^6 -CH₃), 4.11 (s, 2H, CH-Ph), 4.24 (m, 1H, H-3'), 4.32 (d, 1H, $J = 2.1$ Hz, H4'), 4.72 (m, 1H, H-2'), 5.59 (d, 1H, $J = 6.6$ Hz, 3'-OH), 5.69 (d, 1H, $J = 4.5$ Hz, 2'-OH), 6.03 (d, 1H, $J = 6.9$ Hz, H1'), 7.22 (m, 1H, Ph), 7.32 (d, 4H, $J = 4.2$ Hz, Ph), 8.06 (t, 1H, $J = 5.7$ Hz, NHCO), 8.38 (d, 1H, $J = 4.1$ Hz, N^6 -H), 8.54 (s, 1H, H-8), 8.60 (s, 1H, H-5''). ^{13}C NMR (300 MHz, DMSO- d_6): δ 15.16 (CH₃), 27.84 (N^6 -CH₃), 31.72 (CH₂), 34.07 (N -CH₂), 73.64 (C-2' and C-3'), 84.98 (C-4'), 87.87 (C-1'), 119.91 (C-5), 122.11 (C-5''), 126.93, 129.13, 129.22, and 140.07 (Ph), 140.48 (C-8), 147.05, 149.87 (C-4, C-2, and C-4''), 156.12 (C-6), 169.71 (C=O). HRMS (ESI-MS) C₂₂H₂₆N₉O₄ [M + H]⁺: 480.2098 found, 480.2107 calcd. Anal. (C₂₂H₂₅N₉O₄) C, H, N.

2-(4-Cyclopentylmethyl-1,2,3-triazol-1-yl)-9-(5-ethylcarbamoyl- β -D-ribofuranosyl)- N^6 -methyladenine (19)

Compound **31** (60 mg, 0.17 mmol), sodium ascorbate (13 mg, 0.066 mmol) and CuSO₄·5H₂O (3.5 mg, 0.013 mmol) were suspended in 4 mL of ^tBuOH/H₂O (1:1). 3-Cyclopentyl-1-propyne (58 μL , 0.44 mmol) was subsequently added, and the mixture was stirred for 2 days at room temperature. The 2-triazol-1-yl compound precipitated from the reaction medium. Water was added, and the mixture was cooled overnight. The precipitate was filtered off and washed with water and hexane to obtain **19** as a white solid in 33% yield. ^1H NMR (300 MHz, DMSO- d_6): δ 0.89 (t, 3H, CH₃), 1.19–1.28 (m, 2H, cyclopentyl), 1.45–1.75 (m, 6H, cyclopentyl), 2.15–2.25 (m, 1H, CH, cyclopentyl), 2.72 (d, 2H, $J = 7.2$ Hz, CH₂), 3.06 (d, 3H, $J = 4.5$ Hz, N^6 -CH₃), 3.09–3.22 (m, 2H, N -CH₂), 4.24 (dt, 1H, $J = 1.5$ and 4.8 Hz, H-3'), 4.33 (d, 1H, $J = 2.1$ Hz, H-4'), 4.71–7.76 (app q, 1H, $J = 6.6$ Hz, H-2'), 5.61 (d, 1H, $J = 6.3$ Hz, 2'-OH), 5.71 (d, 1H, $J = 4.8$ Hz, 3'-OH), 6.03 (d, 1H, $J = 6.9$ Hz, H-1'), 8.10 (t, 1H, $J = 5.7$ Hz, NHCO), 8.40 (d, 1H, $J = 5.1$ Hz, N^6 -H), 8.54 (s, 1H, H-8), 8.56 (s, 1H, H-5''). ^{13}C NMR (300 MHz, DMSO- d_6): δ 15.17 (CH₃), 25.36 (cyclopentyl), 27.85 (N^6 -CH₃), 31.53 (cyclopentyl), 31.51 (CH₂), 34.07 (CH₂), 73.63 and 73.56 (C-2' and C-3'), 84.99 (C-4'), 87.93 (C-1'), 119.77 (C-5), 121.69 (C-5''), 141.51 (C-8), 147.48 and 149.92 (C-2, C-4, and C-4''), 156.10 (C-6), 169.74 (C=O). HRMS (ESI-MS) C₂₁H₃₀N₉O₄ [M + H]⁺: 472.2415 found, 472.2420 calcd. Anal. (C₂₁H₂₉N₉O₄) C, H, N.

N⁶-(5-Chloro-2-methoxybenzyl)-2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-9-(β-D-ribofuranosyl)adenine (20)

Compound **33** (100 mg, 0.22 mmol), sodium ascorbate (17 mg, 0.086 mmol), and CuSO₄·5H₂O (3.5 mg, 0.017 mmol) were suspended in 4 mL of H₂O/BuOH (1:1). 3-Cyclopentyl-1-propyne (29 μL, 0.44 mmol) was subsequently added, and the mixture was stirred for 2 days at room temperature. The 2-triazol-1-yl compound precipitated from the reaction medium. Water was added, and the mixture was cooled overnight. The precipitate was filtered off and washed with water and hexane to obtain **20** as a white solid in 59% yield. ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.23–1.28 (m, 2H, cyclopentyl), 1.48–1.61 (m, 4H, cyclopentyl), 1.66–1.73 (m, 2H, cyclopentyl), 2.15–2.25 (m, 1H, cyclopentyl), 2.72 (d, 2H, *J* = 7.2 Hz, CH₂-cyclopentyl), 3.56–3.61 (m, 1H, H-5'A), 3.66–3.71 (m, 1H, H-5'B), 3.86 (s, 3H, OCH₃), 3.97 (m, 1H, H-4'), 4.20 (m, 1H, H-3'), 4.64 (m, 1H, H-2'), 4.73 (br s, 2H, N⁶-CH₂), 4.96 (t, 1H, *J* = 6.0 Hz, 5'-OH), 5.22 (d, 1H, *J* = 4.8 Hz, 3'-OH), 5.48 (d, 1H, *J* = 5.7 Hz, 2'-OH), 5.95 (d, 1H, *J* = 6.3 Hz, H-1'), 7.04 (d, 1H, *J* = 9.0 Hz, Ph), 7.25–7.29 (m, 2H, Ph), 8.40 (s, 1H, H-8), 8.81 (s, 1H, H-5''), 8.81 (br s, 1H, N⁶-H). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 25.36 (cyclopentyl), 31.54 (CH₂), 32.54 (cyclopentyl), 38.86 (CH₂), 56.57 (OCH₃), 62.13 (C-5'), 71.15 (C-3'), 74.37 (C-2'), 86.46 (C-4'), 88.07 (C-1'), 113.15 (Ph), 119.58 (C-5), 121.37 (C-5''), 124.66, 128.23, and 129.93 (Ph), 141.37 (C-8), 147.40, 149.66, and 150.12 (C-2, C-4, and C-4'), 155.51 (Ph), 156.33 (C-6). HRMS (ESI-MS) C₂₆H₃₂N₈O₅Cl [M + H]⁺: 571.2184 found, 571.2184 calcd. Anal. (C₂₆H₃₁N₈O₅Cl) C, H, N.

2-Azido-N⁶-methyl-9-(β-D-ribofuranosyl)adenine (23)

Sodium ascorbate (19.4 mg, 0.098 mmol) and CuSO₄·5H₂O (12.2 mg, 0.049 mmol) were added to a mixture of **22** (200 mg, 0.491 mmol), sodium azide (38.3 mg, 0.589 mmol), L-proline (11.3 mg, 0.098 mmol), and sodium carbonate (10.4 mg, 0.098 mmol) in 10 mL of H₂O/BuOH (1:1). The mixture was stirred overnight at 65 °C and was monitored by ¹H NMR. Then 50 mL of dilute NH₄OH was added and the crude mixture extracted with ethyl acetate (3 × 60 mL). The organic layer was washed with brine (60 mL), dried over MgSO₄, and purified on a silica gel column (CH₂Cl₂/MeOH, 95:5) to afford compound **23** as a slightly yellow solid in 66% yield. ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.91 (d, 3H, *J* = 4.4 Hz, N⁶-CH₃), 3.48–3.55 (m, 1H, H-5'A), 3.58–3.66 (m, 1H, H-5'B), 3.90 (dd, 1H, *J* = 3.8 and 7.3 Hz, H-4'), 4.10 (dd, 1H, *J* = 4.7 and 9.7 Hz, H-3'), 4.53 (app q, 1H, *J* = 5.9 Hz, H-2'), 5.04 (dd, 1H, *J* = 5.2 and 6.2 Hz, 5'-OH), 5.19 (d, 1H, *J* = 5.0 Hz, 3'-OH), 5.43 (d, 1H, *J* = 6.2 Hz, 2'-OH), 5.78 (d, 1H, *J* = 6.2 Hz, H-1'), 8.12 (d, *J* = 4.4 Hz, N⁶-H), 8.27 (s, 1H, H-8). Small peaks from 1/6 tetrazole tautomeric form: δ 3.15 (d, 3H, *J* = 5.0 Hz, N⁶-CH₃), 3.95 (d, H-4'), 4.15 (d, H-3'), 5.51 (d, 2'-OH), 5.94 (d, H-1'), 8.51 (s, H-8). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 27.54 (N⁶-CH₃), 62.21 (C-5'), 71.17 (C-3'), 74.12 (C-2'), 86.35 (C-4'), 88.01 (C-1'), 118.07 (C-5), 139.99 (C-8), 156.06 and 156.20 (C-2 and C-6). Small peaks from 1/6 tetrazole tautomeric form: δ 31.89 (N⁶-CH₃), 61.79 (C-5'), 70.77 (C-3'), 74.37 (C-4'), 112.30 (C-12), 142.91 (C-11), 147.60 (C-6). HRMS (ESI-MS) C₁₁H₁₅N₈O₄ [M + H]⁺: 323.1208 found, 323.1216 calcd. Anal. (C₁₁H₁₄N₈O₄) C, H, N.

N⁶-Methyl-9-(β-D-ribofuranosyl)-2-[2-trimethylsilylethyn-1-yl]adenine (24)

Compound **22** (500 mg, 1.23 mmol), CuI (12 mg, 0.062 mmol), and (Ph₃P)₃PCl₂ were dissolved in 9 mL of DMF. Triethylamine (205 μL, 1.47 mmol) and trimethylsilylacetylene (210 mg, 1.47 mmol) were added, and the reaction mixture was stirred overnight. After solvent evaporation, the residue was dissolved in CH₂Cl₂ and filtered through a pad of Celite. Purification on a silica gel column (CH₂Cl₂/MeOH, 95:5) yielded 305 mg (66%) of compound **23**. ¹H NMR (300 MHz, DMSO-*d*₆): δ 0.00 (9H, s, (CH₃)₃Si), 2.7 (3H, N⁶-CH₃), 3.26–3.34 (m, 1H, H-5'A), 3.37–3.44 (m, 1H, H-5'B), 3.68 (dd, 1H, *J* = 3.5 Hz, H-4'), 3.86 (dd, 1H, *J* = 3.4 and 8.2 Hz, H-3'), 4.23 (app q, 1H, *J* = 5.9 Hz, H-2'), 4.87 (t, 1H, *J* = 5.0, 5'-OH), 4.94 (d, 1H, *J* = 4.99 Hz, 3'-OH), 5.21 (d, 1H, *J* = 6.2 Hz, 2'-OH), 5.63 (d, 1H, *J* = 6.2 Hz, H-1'), 7.69 (br s, 1H, N⁶-H), 8.19 (s, 1H, H-8). HRMS (ESI-MS) C₁₆H₂₄N₅O₄Si: [M + H]⁺: 378.1586 found; 378.1597 calcd.

2-Ethynyl-N⁶-methyl-9-(β-D-ribofuranosyl)purine (25)

An amount of 300 mg (0.8 mmol) of compound **24** was dissolved in 7 N ammonia in methanol and stirred for 2 h at 0 °C. After solvent evaporation, the residue was purified by silica gel chromatography (CH₂Cl₂/MeOH, 95:5) to obtain 160 mg (65%) of derivative **25**. ¹H NMR (300 MHz, DMSO-*d*₆): δ 2.91 (s, 3H, N⁶-CH₃), 3.48–3.56 (m, 1H, H-5'A), 3.61–3.68 (m, 1H, H-5'B), 3.92 (m, 1H, H-4'), 4.02 (s, 1H, C≡CH), 4.11 (dd, 1H, *J* = 5.0 and 8.2 Hz, H-3'), 4.53 (app q, 1H, *J* = 5.9 Hz, H-2'), 5.15 (m, 2H, 3'-OH and 5'-OH), 5.44 (d, 1H, *J* = 6.15 Hz, 2'-OH), 5.84 (d, 1H, *J* = 6.16 Hz, H-1'), 7.95 (br s, 1H, N⁶-H), 8.40 (s, 1H, H-8). HRMS (ESI-MS) C₁₃H₁₆N₅O₄ [M + H]⁺: 306.1197 found; 306.1202 calcd.

1-Deoxy-1-(6-methylamino-2-iodo-9H-purin-9-yl)-2,3-O-isopropylidene-β-D-ribofuranuronic Acid (27)

To a stirred solution of 3.8 g (8.5 mmol) of **26** in 560 mL of H₂O were added 1.4 g of KOH and, dropwise, a solution of 4.03 g (25.5 mmol) of KMnO₄ in 110 mL of H₂O. The mixture was stirred in the dark for 20 h, cooled to 0 °C, and quenched with 30 mL of 7% H₂O₂. The mixture was filtered through Celite. The filtrate was concentrated in vacuo and then acidified to pH 4 with 3 N HCl. The resulting precipitate was filtered off and successively washed with water and ether to give 2.98 g (76%) of **27** as a white solid. ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.36 (s, 3H, CH₃), 1.51 (s, 3H, CH₃), 2.89 (d, 3H, *J* = 3.3 Hz, N⁶-CH₃), 4.68 (d, 1H, *J* = 1.8 Hz, H-4'), 5.40 (d, 1H, *J* = 6.0 Hz, H-2'), 5.47 (dd, 1H, *J* = 6.0 and 1.8 Hz, H-3'), 6.28 (s, 1H, H-1'), 8.08 (d, 1H, *J* = 3.3 Hz, N⁶-H), 8.16 (s, 1H, H-8). HRMS (ESI-MS) C₁₄H₁₆N₅O₅I [M + H]⁺: 462.0273 found; 462.0276 calcd.

9-(5-Ethylcarbamoyl-β-D-ribofuranosyl)-2-iodo-N⁶-methyladenine (30)

p-Nitrophenol (402 mg, 2.89 mmol) and 1-[3-(dimethylamino) propyl]-3-ethylcarbodiimide hydrochloride (506 mg, 2.65 mmol) were added to a solution of **27** (1.11 g, 2.41 mmol) in 10 mL of dry DMF. The reaction mixture was stirred for 3 h at room temperature and cooled to 0 °C, and 1.6 mL (24.1 mmol) of ethylamine was added. The solution turned yellow immediately and was further stirred for 1 h at room temperature. After evaporation of the volatiles, the residue was partitioned between ethyl acetate (3 × 100 mL) and H₂O (100 mL). The organic layer was washed with brine (100 mL), dried over MgSO₄, and concentrated to

dryness. The residue was dissolved in 80% aqueous TFA (20 mL) and stirred for 2 h at room temperature. The mixture was concentrated in vacuo, coevaporated several times with EtOH, and purified by silica gel chromatography (CH₂Cl₂/MeOH, 96:4). Compound **30** was obtained as a white solid in 78% yield (840 mg). ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.05 (t, 3H, *J* = 7.2 Hz, CH₃), 2.91 (d, 3H, *J* = 4.4 Hz, N⁶-CH₃), 3.19–3.29 (m, 2H, N-CH₂), 4.16 (dt, 1H, *J* = 2.1 and 4.4 Hz, H-3'), 4.31 (d, 1H, *J* = 2.1 Hz, H-4'), 4.58 (app q, 1H, *J* = 5.6 Hz, H-2'), 5.59 (d, 1H, *J* = 6.5 Hz, 2'-OH), 5.71 (d, 1H, *J* = 4.7 Hz, 3'-OH), 5.92 (d, 1H, *J* = 7.1 Hz, H-1'), 8.12 (t, 1H, *J* = 5.5 Hz, NHCO), 8.19 (d, 1H, *J* = 4.4 Hz, N⁶-H), 8.38 (s, 1H, H-8). HRMS (ESI-MS) C₁₃H₁₈N₆O₄I [M + H]⁺: 449.0429 found, 449.0436 calcd.

2-Azido-9-(5-ethylcarbamoyl-β-D-ribofuranosyl)-N⁶-methyladenine (**31**)

Sodium ascorbate (69 mg, 0.34 mmol) and CuSO₄·5H₂O (5.6 mg, 0.17 mmol) were added to a mixture of **30** (780 mg, 1.74 mmol), sodium azide (226 mg, 3.48 mmol), L-proline (40 mg, 0.35 mmol), and sodium carbonate (37 mg, 0.35 mmol) in 20 mL of H₂O/*i*BuOH (1:1). The mixture was stirred for 2 days at 65 °C and monitored by ¹H NMR. An amount of 100 mL of dilute NH₄OH was added, and the crude mixture was extracted with ethyl acetate (5 × 150 mL) and washed with brine (150 mL). The organic layer was dried over MgSO₄ and purified on a silica gel column (CH₂Cl₂/MeOH, 96:4) to afford compound **31** as a white solid in 79% yield (500 mg). ¹H NMR (300 MHz, DMSO-*d*₆): δ 1.06 (t, 3H, *J* = 7.2 Hz, CH₃), 2.96 (d, 3H, *J* = 4.0 Hz, N⁶-CH₃), 3.16–3.29 (m, 2H, N-CH₂), 4.14 (dt, 1H, *J* = 1.8 and 4.8 Hz, H-3'), 4.29 (d, 1H, *J* = 1.8, H-4'), 4.53–4.59 (app q, 1H, *J* = 6.3 Hz, H-2'), 5.52 (d, 1H, *J* = 6.3 Hz, 2'-OH), 5.68 (d, 1H, *J* = 4.8 Hz, 3'-OH), 5.90 (d, 1H, *J* = 7.2 Hz, H-1'), 8.20 (d, 1H, *J* = 4.0 Hz, N⁶-H), 8.35 (s, 1H, H-8), 8.49 (t, 1H, *J* = 6.0 Hz, NHCO). Small peaks from 1/5 tetrazole tautomeric form: δ 1.08–1.12 (t, 3H, *J* = 7.2 Hz, CH₃), 4.34 (d, 1H, *J* = 2.1 Hz, H-4'), 4.67–4.73 (app q, 1H, *J* = 7.2 Hz, H-2'), 5.54 (d, 1H, *J* = 4.5 Hz, 2'-OH) 6.00 (d, 1H, *J* = 7.2 Hz, H-1'). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 15.48 (CH₃), 27.52 (N⁶-CH₃), 33.94 (N-CH₂), 73.06 and 73.75 (C-2' and C-3'), 85.15 (C-4'), 88.09 (C-1'), 118.36 (C-5), 140.69 (C-8), 156.032 and 156.143 (C-2 and C-4), 169.79 (C-6). HRMS (ESI-MS) C₁₃H₁₈N₉O₄ [M + H]⁺: 364.1473 found; 364.1481 calcd. Anal. (C₁₃H₁₇N₉O₄) C, H, N.

N⁶-(5-Chloro-2-methoxybenzyl)-2-iodo-9-(β-D-ribofuranosyl)-adenine (**32**)

Compound **21** (1 g, 1.86 mmol) was dissolved in EtOH (30 mL). 5-Chloro-2-methoxybenzylammonium chloride (580 mg, 2.79 mmol) and Et₃N (392 μL, 2.79 mmol) were added, and the solution was refluxed overnight. The mixture was concentrated to dryness, dissolved in 7 N NH₃ in methanol, and stirred at room temperature for 2 h to deprotect the 2'-hydroxyl group. The volatiles were removed under reduced pressure, and the residue was purified by silica gel column (CH₂Cl₂/MeOH, 97:3). The product, compound **32**, was realized in 80% yield. ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.51–3.58 (m, 1H, H-5'A), 3.63–3.68 (m, 1H, H-5'B), 3.85 (s, 3H, OCH₃), 3.94 (m, 1H, H-4'), 4.13 (m, 1H, H-3'), 4.52–4.59 (m, 3H, N⁶-CH₂ and H-2'), 5.03 (t, 1H, *J* = 5.6 Hz, 5'-OH), 5.21 (d, 1H, *J* = 5.0 Hz, 3'-OH), 5.48 (d, 1H, *J* = 5.8 Hz, 2'-OH), 5.83 (d, 1H, *J* = 6.2 Hz, H-1'), 7.03 (d, 1H, *J* = 8.8 Hz, Ph), 7.16 (d, 1H, *J* = 2.7 Hz, Ph), 7.29 (dd, 1H, *J* = 2.7 and 8.8 Hz, Ph), 8.35 (s, 1H, H-8), 8.62 (br s, 1H, N⁶-H). HRMS (ESI-MS) C₁₈H₂₀N₅O₅-ICl [M + H]⁺: 548.0204 found; 548.0199 calcd.

2-Azido-*N*⁶-(5-chloro-2-methoxybenzyl)-9-(β -D-ribofuranosyl) adenine (**33**)

Sodium ascorbate (14 mg, 0.073 mmol) and CuSO₄·5H₂O (9 mg, 0.037 mmol) were added to a mixture of **32** (200 mg, 0.365 mmol), sodium azide (47 mg, 0.73 mmol), L-proline (8 mg, 0.073 mmol), and sodium carbonate (8 mg, 0.073 mmol) in 4 mL of H₂O/*t*-BuOH (1:1). The mixture was stirred for 2 days at 65 °C and monitored by ¹H NMR. An amount of 10 mL of dilute NH₄-OH was added, and the crude mixture was extracted with ethyl acetate (5 × 15 mL) and washed with brine (15 mL). The organic layer was dried over MgSO₄ and purified on a silica gel column (CH₂Cl₂/MeOH, 97:3) to afford compound **33** as a white solid in 82% yield. ¹H NMR (300 MHz, DMSO-*d*₆): δ 3.51–3.56 (m, 1H, H5'-A), 3.60–3.66 (m, 1H, H5'-B), 3.83 (s, 3H, OCH₃), 3.93 (m, 1H, H 4'), 4.13 (m, 1H, H-3'), 4.56–4.62 (m, 3H, *N*⁶-CH₂ and H-2'), 5.03 (t, 1H, *J* = 5.4 Hz, 5'-OH), 5.17 (d, 1H, *J* = 4.8 Hz, 3'-OH), 5.41 (d, 1H, *J* = 6.3 Hz, 2'-OH), 5.81 (d, 1H, *J* = 6.0 Hz, H-1'), 7.02 (d, 1H, *J* = 8.7 Hz, Ph), 7.15 (d, 1H, *J* = 3.0 Hz, Ph), 7.28 (dd, 1H, *J* = 2.7 and 8.7 Hz, Ph), 8.34 (s, 1H, H-8), 8.63 (br s, 1H, *N*⁶-H). ¹³C NMR (300 MHz, DMSO-*d*₆): δ 38.59 (CH₂), 56.49 (OCH₃), 62.19 (C-5'), 71.15 (C-3'), 74.13 (C-2'), 86.36 (C-4'), 88.13 (C-1'), 113.02 (Ph), 119.58 (C-5), 124.29 (Ph), 128.10 (Ph), 129.93 (Ph), 140.43 (C-8), 150.69 (C-4), 155.51 (Ph and C-2), 156.33 (C-6). HRMS (ESI-MS) C₁₈H₂₀N₈O₅Cl [M + H]⁺: 463.1248 found, 463.1245 calcd. Anal. (C₁₈H₁₉N₈O₅Cl) C, H, N.

Cell Culture and Membrane Preparation

CHO cells expressing recombinant human ARs or the rat A₃AR were cultured in DMEM (Dulbecco's modified Eagle's medium) and F12 (1:1) supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 μ g/mL streptomycin, and 2 μ mol/mL glutamine. After harvest and homogenization, the cells were centrifuged at 500*g* for 10 min. The pellet was resuspended in 50 mM Tris-HCl buffer (pH 7.4) containing 10 mM MgCl₂ and 1 mM EDTA. The suspension was homogenized with an electric homogenizer for 10 s and was then recentrifuged at 20000*g* for 20 min at 4 °C. The resulting pellets were resuspended in buffer containing 3 units/mL of adenosine deaminase, and the suspension was stored at –80 °C prior to the binding experiments. The protein concentration was measured using the Bradford assay.³⁹

Radioligand Binding Studies

For the A₃AR binding experiments, the procedures were similar to those previously described.¹⁹ Briefly, each tube contained 100 μ L of membrane suspension, 50 μ L of [¹²⁵I]-AB-MECA ([¹²⁵I]*N*⁶-(4-amino-3-iodobenzyl)adenosine-5'-*N*-methyluronamide, final concentration of 0.5 nM), and 50 μ L of increasing concentrations of compounds in Tris-HCl buffer (50 mM, pH 7.4) containing 10 mM MgCl₂ and 1 mM EDTA. Nonspecific binding was determined using 10 μ M NECA (adenosine-5'-*N*-ethyluronamide). The mixtures were incubated at 25 °C for 60 min. Binding reactions were terminated by filtration through Whatman GF/B filters under reduced pressure using a MT-24 cell harvester (Brandel, Gaithersburg, MD). Filters were washed three times with ice-cold buffer. Radioactivity was determined in a Beckman 5500B γ -counter. The binding of [³H]CCPA (2-chloro-*N*⁶-cycloptyladenosine) to the recombinant hA₁AR and the binding of [³H]CGS21680 (2-[*p*-

(2-carboxyethyl)phenylethylamino]-5'-*N*-ethylcarboxamidoadenosine) to the recombinant hA_{2A}AR was performed as previously described.^{20,44}

Cyclic AMP Accumulation Assay

Intracellular levels of 3',5'-cyclic AMP were measured by the competitive protein binding method.³² CHO cells expressing recombinant human⁴⁰ ARs were harvested by trypsinization. After resuspension in the medium, cells were plated in 24-well plates in 0.5 mL of medium/well. After 24 h the medium was removed and cells were washed three times with 1 mL/well of DMEM containing 50 mM *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid, pH 7.4. Cells were then treated with agonists and/or test compounds in the presence of rolipram (10 μ M) and adenosine deaminase (3 units/mL) and incubated at 37 °C. For the A₃AR, after 45 min forskolin (10 μ M) was added to the medium, and incubation was continued for an additional 15 min. The reaction was terminated upon removal of the medium, and the cells were lysed with 200 μ L/well of 0.1 M ice-cold HCl. The cell lysate was resuspended and stored at -20 °C. For determination of cyclic AMP production, protein kinase A (PKA) was incubated with [³H]cyclic AMP (2 nM) in K₂HPO₄/EDTA buffer (K₂HPO₄, 150 mM; EDTA, 10 mM), 20 μ L of the cell lysate, and 30 μ L of 0.1 M HCl. Bound radioactivity was separated by rapid filtration through Whatman GF/C filters under reduced pressure and washed once with cold buffer. Bound radioactivity was subsequently measured by scintillation spectrometry. Calculation of the relative maximal efficacy at the A₃AR was determined at a fixed concentration of the nucleoside analogue (10 μ M) and expressed as a relative percent of the effect of 10 μ M NECA determined in each experiment, which typically reached \times 50% inhibition of the forskolin stimulated cyclase.

Molecular Modeling

All calculations were performed on a Silicon Graphics Octane2 workstation (600 MHz IP30 processor, MIPS R14000). Compound **10**, 2-(4-cyclopentylmethyl-1,2,3-triazole)-*N*⁶-methyladenosine, was constructed with the use of the Sketch Molecule of SYBYL 7.1 (Tripos Inc., 1699 South Hanley Road, St. Louis, MO 63144). A grid search was performed in which flexible bonds were rotated by 0° and 180° for t1 (C₅-C₆-N⁶-C_{Me}) at the N⁶ position, t2 (4'O-4'C-5'C-5'OH) at the 5'-position, and t3 (N₃-C₂-N_{1'}-N_{2'}) and by 60°, 180°, and -60° for t4 (N_{3'}-C_{4'}-C_{Me}-C_{Cyc}) and t5 (C_{4'}-C_{Me}-C_{Cyc}-C_{Cyc}) at the C2 position. The low-energy conformers from the grid search were reoptimized, removing all torsional constraints. Merck molecular force field (MMFF)⁴¹ and charges were applied with the use of distance-dependent dielectric constants and the conjugate gradient method until the gradient reached 0.05 kcal·mol⁻¹·Å⁻¹. After the low-energy conformers from the result of the grid search were clustered, the representative ones from all groups were reoptimized by semiempirical molecular orbital calculations with the PM3 method in the MOPAC 6.0 package.⁴²

A human A₃AR model (PDB code 1OEA) constructed by homology to the X-ray structure of bovine rhodopsin with 2.8 Å resolution (PDB code 1F88)³⁸ was used for the docking study. All atom types were assigned by the Amber7_FF99 force field.⁴³ Amber charges for protein and MMFF charges for ligand were calculated. The starting geometry of the ligand

conformation was chosen from the human A₃AR complex model with Cl-IB-MECA,¹⁹ which was already validated by point mutation. The ribose binding position was fixed, using an atom-by-atom fitting method for the carbon atoms of the ribose ring. To determine the binding region of the 2-(4-cyclopentylmethyl-1,2,3-triazole) moiety at the adenine 2 position, the flexible bond defining a χ_1 (O–C_{1'}–N₉–C₄) angle was searched while docked within the putative binding cavity through various low-energy conformers with diverse t1–t5 angles, rotating by –60°, –110°, and –160°, assuming an anti conformation. Several conformations without any steric bump were selected for further optimization. The initial structures of all complexes were optimized using the Amber force field with a fixed dielectric constant of 4.0 and a terminating gradient of 0.05 kcal·mol⁻¹·Å⁻¹.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This research was supported in part by the Intramural Research Program of the NIH, National Institute of Diabetes and Digestive and Kidney Diseases.

References

1. Müller CE. Adenosine receptor ligands. Recent developments. Part I. Agonists. *Curr Top Med Chem.* 2000; 7:1269–1288.
2. Linden J. Cloned adenosine A₃ receptors: pharmacological properties, species differences and receptor functions. *Trends Pharmacol Sci.* 1994; 15:298–306. [PubMed: 7940998]
3. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, Linden J. International Union of Pharmacology XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev.* 2001; 53:527–552. [PubMed: 11734617]
4. Jacobson KA, Gao Z-G. Adenosine receptors as therapeutic targets. *Nat Rev Drug Discovery.* 2006; 5:247–246. [PubMed: 16518376]
5. Fishman P, Bar-Yehuda S. Pharmacology and therapeutic applications of A₃ receptor subtype. *Curr Top Med Chem.* 2003; 3:463–469. [PubMed: 12570762]
6. Fishman P. The A₃ adenosine receptor as a new target for cancer therapy and chemoprotection. *Exp Cell Res.* 2001; 269:230–236. [PubMed: 11570815]
7. Müller CE. Medicinal chemistry of adenosine A₃ receptor ligands. *Curr Top Med Chem.* 2003; 3:445–462. [PubMed: 12570761]
8. Jacobson KA, Moro S, Kim YC, Li AH. A₃ adenosine receptors: Protective vs. damaging effects identified using novel agonists and antagonists. *Drug Dev Res.* 1998; 45:113–124.
9. Brambilla R, Cattabeni F, Ceruti S, Barbieri D, Franceschi C, Kim Y, Jacobson KA, Klotz KN, Lohse MJ, Abbracchio MP. Activation of the A₃ adenosine receptor effects cell cycle progression and cell growth. *Naunyn-Schmiedeberg's Arch Pharmacol.* 2000; 361:225–234. [PubMed: 10731034]
10. von Lubitz DK, Lin RC, Popik P, Carter MF, Jacobson KA. Adenosine A₃ receptor stimulation and cerebral ischemia. *Eur J Pharmacol.* 1994; 263:59–67. [PubMed: 7821362]
11. von Lubitz DK, Carter MF, Deutsch SI, Lin RC, Mastrapaolo J, Meshulam Y, Jacobson KA. The effects of adenosine A₃ adenosine receptor stimulation on seizures in mice. *Eur J Pharmacol.* 1995; 275:23–29. [PubMed: 7774659]
12. Borea, PA.; Baraldi, PG.; Chen, SF.; Leung, E. Enhancing treatment of MDR cancer with adenosine A₃ antagonists. *PCT Int Appl WO.* 2004000224. 2003.
13. Civan MM, Macknight ADC. The ins and outs of aqueous humour secretion. *Exp Eye Res.* 2004; 78:625–631. [PubMed: 15106942]

14. Okamura T, Kurogi Y, Hashimoto K, Sato S, Nishikawa H, Kiryu K, Nagao Y. Structure–activity relationships of adenosine A₃ receptor ligands: New potential therapy for the treatment of glaucoma. *Bioorg Med Chem Lett*. 2004; 14:3775–3779. [PubMed: 15203160]
15. Yang H, Avila MY, Peterson-Yantorno K, Coca-Prados M, Stone RA, Jacobson KA, Civan MM. The cross-species A₃ adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. *Curr Eye Res*. 2005; 30:747–754. [PubMed: 16146920]
16. Poulsen SA, Quinn RJ. Adenosine receptors: New opportunities for future drugs. *Bioorg Med Chem*. 1998; 6:619–641. [PubMed: 9681130]
17. Perreira M, Jiang JK, Klutz AM, Gao ZG, Shainberg A, Lu C, Thomas CJ, Jacobson KA. “Reversine” and its 2-substituted adenine derivatives as potent and selective A₃ adenosine receptor antagonists. *J Med Chem*. 2005; 48:4910–4918. [PubMed: 16033270]
18. Lenzi O, Colotta V, Catarzi D, Varano F, Filacchioni G, Martini C, Trincavelli L, Ciampi O, Varani K, Marighetti F, Morizzo E, Moro S. 4-Amido-2-aryl-1,2,4-triazolo[4,3-*a*]quinoxalin-1-ones as new potent and selective human A₃ adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies. *J Med Chem*. 2006; 49:3916–3925. [PubMed: 16789747]
19. Gao ZG, Kim SK, Biadatti T, Chen W, Lee K, Barak D, Kim SG, Johnson CR, Jacobson KA. Structural determinants of A₃ adenosine receptor activation: Nucleoside ligands at the agonist/antagonist boundary. *J Med Chem*. 2002; 45:4471–4484. [PubMed: 12238926]
20. Gao ZG, Blaustein JB, Gross AS, Melman N, Jacobson KA. N⁶-Substituted adenosine derivatives: selectivity, efficacy and species differences at A₃ adenosine receptors. *Biochem Pharmacol*. 2003; 65:1675–1684. [PubMed: 12754103]
21. Volpini R, Constanzi S, Lambertucci C, Vittori S, Klotz KN, Lorenzen A, Cristalli G. Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A₃ adenosine receptor. *Bioorg Med Chem Lett*. 2001; 11:1931–1934. [PubMed: 11459663]
22. Elzein E, Palle V, Wu Y, Maa T, Zeng D, Zablocki J. 2-Pyrazolyl-N⁶-substituted adenosine derivatives as high affinity and selective adenosine A₃ receptor agonists. *J Med Chem*. 2004; 47:4766–4773. [PubMed: 15341491]
23. Volpini R, Constanzi S, Lambertucci C, Taffi S, Vittori S, Klotz KN, Cristalli G. N⁶-Alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A₃ receptor and a starting point for searching A_{2B} ligands. *J Med Chem*. 2002; 45:3271–3279. [PubMed: 12109910]
24. Lewis WG, Green LG, Grynszpan F, Radi Z, Carlier PR, Taylor P, Finn MG, Sharpless KB. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. *Angew Chem, Int Ed*. 2002; 41:1053–1057.
25. Alvarez R, Velázquez S, San-Félix A, Aquaro S, De Clercq E, Perno CF, Karlsson A, Balzarini J, Camarassa MJ. 1,2,3-Triazol-[2',5'-bis-*O*-(*tert*-butyldimethylsilyl)-β-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1,2''-oxothiole 2'',2''-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity. *J. Med. Chem*. 1994; 37: 4185–4198. (b) Gunji, H., Vasella, A. Oligonucleotides with a nucleobase-including backbone. Part 4. A convergent synthesis of ethylenediyl-linked adenosine tetramers *Helv. Chim. Acta* 2000; 83: 3229–3245. (c) Epple, R., Kudirka, R., Greenberg, W. A. Solidphase synthesis of nucleoside analogs. *J. Comb. Chem*. 2003; 5: 292–310. (d) O'Mahony, G., Ehrman, E., Grøtli, M. Synthesis of adenosine-based fluorosides containing a novel heterocyclic ring system. *Tetrahedron Lett*. 2005; 46: 4745–6748. (e) Moukha-Chafiq, O., Taha, M. L., Lazrek, H. B., Pannecouque, C., Witvrouw, M., De Clercq, E., Barascut, L., Imbach, J. L. Synthesis and biological activity of 4-substituted 1-[1-(2-hydroxymethoxy)-methyl-1,2,3-triazol-(4 & 5)-ylmethyl]-1*H*-pyrazolo-[3,4-*d*]pyrimidines. *Nucleosides, Nucleotides Nucleic Acids* 2001; 20: 1797–1810. (f) Moukha-Chafiq, O., Taha, M. L., Lazrek, H. B., Vasseur, J. J., Pannecouque, C., Witvrouw, M., De Clercq, E. Synthesis and biological evaluation of some 4-substituted 1-[1-(2-hydroxybutyl)-1,2,3-triazol-(4 & 5)-ylmethyl]-1*H*-pyrazolo[3,4-*d*]pyrimidines. *Nucleosides, Nucleotides Nucleic Acids* 2001; 20: 1811–1821. (g) Wigerinck, P., Van Aerschot, A., Claes, P., Balzani, J., Declercq, E., Herdewijn, P. 3'-(1,2,3-Triazol-1-yl)-2',3'-dideoxythymidine and 3'-(1,2,3-triazol-1-yl)-2',3'-dideoxyuridine. *J Heterocycl Chem*. 1989; 26:1635–1642.

26. Matsuda A, Shinozaki M, Yamaguchi T, Homma H, Nomoto R, Miyasaka T, Watanabe Y, Abiru T. Nucleosides and nucleotides. 103. 2-Alkynyladenosines: a novel class of selective adenosine A₂ receptor agonists with potent antihypertensive effects. *J Med Chem.* 1992; 35:241–252. [PubMed: 1732541]
27. Feldman AK, Colasson B, Fokin VV. One-pot synthesis of 1,4-disubstituted 1,2,3-triazoles from in situ generated azides. *Org Lett.* 2004; 6:3897–3899. [PubMed: 15496058]
28. Temple C Jr, Kussner CL, Montgomery JA. Studies on the azidomethine–tetrazole equilibrium. V. 2- and 6-azidopurines. *J Org Chem.* 1966; 31:2210–2215.
29. Lioux T, Gosselin G, Mathé C. Azido/tetrazole tautomerism in 2-azidoadenine beta-D-pentofuranonucleoside derivatives. *Eur J Org Chem.* 2003; 20:3997–4002.
30. Himo F, Lovell T, Hilgraf R, Rostovtsev VV, Noodleman L, Sharpless KB, Fokin VV. Copper(I)-catalysed synthesis of azoles. DFT study predicts unprecedented reactivity and intermediates. *J Am Chem Soc.* 2005; 127:210–216. [PubMed: 15631470]
31. Umino T, Yoshioka K, Saitoh Y, Minakawa N, Nakata H, Matsuda A. Nucleosides and Nucleotides. 200. Reinvestigation of 5'-N-ethylcarboxamidoadenosine derivatives: structure–activity relationship for P₃ purinoceptor-like proteins. *J Med Chem.* 2001; 44:208–214. [PubMed: 11170630]
32. Nordstedt C, Fredholm BB. A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body-fluid. *Anal Biochem.* 1990; 189:234.
33. Salvatore CA, Jacobson MA, Taylor HE, Linden J, Johnson RG. Molecular-cloning and characterisation of the human-A₃ adenosine receptor. *Proc Natl Acad Sci US A.* 1993; 90:10365–10369.
34. Ohno M, Gao ZG, Van Rompaey P, Tchilibon S, Kim SK, Harris BA, Blaustein J, Gross AS, Duong HT, Van Calenbergh S, Jacobson KA. Modulation of adenosine receptor affinity and intrinsic efficacy in nucleosides substituted at the 2-position. *Bioorg Med Chem.* 2004; 12:2995–3007.
35. Cosyn L, Gao ZG, Van Rompaey P, Lu C, Jacobson KA, Van Calenbergh S. Synthesis of hypermodified adenosine derivatives as selective adenosine A₃ receptor ligands. *Bioorg Med Chem.* 2006; 14:1403–1412. [PubMed: 16266807]
36. Gao ZG, Jeong LS, Moon HR, Kim HO, Choi WJ, Shin DH, Elhalem E, Comin MJ, Melman N, Mamedova L, Gross AS, Rodriguez JB, Jacobson KA. Structural determinants of efficacy at A₃ adenosine receptors: Modification of the ribose moiety. *Biochem Pharmacol.* 2004; 67:893–901. [PubMed: 15104242]
37. Tchilibon S, Kim SK, Gao ZG, Harris BA, Blaustein J, Gross AS, Melman N, Jacobson KA. Exploring distal regions of the A₃ adenosine receptor binding site: Sterically-constrained N⁶-(2-phenylethyl)adenosine derivatives as potent ligands. *Bioorg Med Chem.* 2004; 12:2021–2034. [PubMed: 15080906]
38. Palczewski K, Kumasaka T, Hori T, Behnke CA, Motoshima H, Fox BA, Le Trong I, Teller DC, Okada T, Stenkamp TE, Yamamoto M, Miyano M. Crystal structure of rhodopsin: a G protein-coupled receptor. *Science.* 2000; 289:739–745. [PubMed: 10926528]
39. Bradford MM. Rapid and sensitive method for quantification of microgram quantities of protein utilizing principle of protein–dye binding. *Anal Biochem.* 1976; 72:248. [PubMed: 942051]
40. Baraldi PG, Cacciari B, Pineda de las Infantas MJ, Romagnoli R, Spalluto G, Volpini R, Constanzi S, Vittori S, Cristalli G, Melman N, Park K, Jacobson KA. Synthesis and biological activity of a new series of N⁶-arylcarbamoyl, 2-(ar)-alkynyl-N⁶-arylcarbamoyl, and N⁶-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A₁ and A₃ adenosine receptor agonists. *J Med Chem.* 1998; 41:3174–3185. [PubMed: 9703463]
41. Halgren TA. MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. *J Comput Chem.* 1999; 20:730–748.
42. Stewart JJP. MOPAC: A semiempirical molecular orbital program. *J Comput-Aided Mol Des.* 1990; 4:1–105. [PubMed: 2197373]

43. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM Jr, Ferguson DM, Spellmeyer DC, Fox T, Caldwell JW, Kollman PA. A second generation force field for the simulation of proteins nucleic acids and organic molecules. *J Am Chem Soc.* 1995; 117:5179–5197.
44. Hutchison AJ, Williams M, de-Jesus R, Yokoyama R, Oei HH, Ghai GR, Webb RL, Zoganas HC, Stone GA, Jarvis MF. 2-(Arylkylamino)adenosine-5'-uronamides. A new class of highly selective adenosine A₂ receptor ligands. *J Med Chem.* 1990; 33:1919–1924. [PubMed: 2362269]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript





Figure 1.


(A) Docking complexes of compound **10**, 2-(4-cyclopentylmethyl-1,2,3-triazol-1-yl)-N⁶-methyladenosine. (B) Superimposition of Cl-IB-MECA in red and compound **10** in color by atom type. Residues that were within 5 Å to the ligand in this putative binding site were L91 (3.33), T94 (3.36), H95 (3.37), Q167 (EL2), F168 (EL2), M172 (EL2), S181 (5.42), M177 (5.38), V178 (5.39), F182 (5.43), W243 (6.48), L246 (6.51), S247 (6.52), N250 (6.55), C251 (6.56), I268 (7.39), S271 (7.42), and H272 (7.43). The ligand is represented by a ball-and-stick model. The H-bonds are indicated with yellow dots. By use of the MOLCAD ribbon surface program, the A₃AR is shown in a ribbon model with different colors for each TM (TM1, red; TM2, orange; TM3, yellow; TM4, green; TM5, cyan; TM6, blue; TM7, purple; H8, violet).




Scheme 1.

Synthesis of 1,2,3-Triazol-1-yl Analogues of *N*⁶-Methyladenosine **1–11**^a

^a Reagents and conditions: (a) CH₃NH₂ in THF, 2 days; (b) CuSO₄·5H₂O, sodium ascorbate, L-proline, Na₂CO₃, NaN₃, H₂O/^tBuOH 1:1, 60 °C; (c) CuSO₄·5H₂O, sodium ascorbate, alkyne, H₂O/^tBuOH 3:1, room temp.




Scheme 2.
Azido/Tetrazole Tautomerism of a 2-Substituted Adenosine Derivative **23**

**Scheme 3.**


Synthesis of 1,2,3-Triazol-4-yl Analogues of *N*⁶-Methyladenosine **12–14**^a

^a Reagents and conditions: (a) trimethylsilylacetylene, CuI, (Ph₃P)₃PdCl₂, DMF; (b) 7 N NH₃ in MeOH, 0 °C; (c) CuSO₄·5H₂O, sodium ascorbate, alkyne, H₂O/^tBuOH 3:1, room temp.

**Scheme 4.**

Synthesis of 1,2,3-Triazol-1-yl Analogues of *N*⁶-Methyladenosine-5'-*N*-ethyluronamide **15–19**^a

^a Reagents and conditions: (a) KMnO₄, KOH, room temp, 20 h; (b) *p*-nitrophenol, EDCI, DMF, room temp; (c) ethylamine; (d) 80% TFA/H₂O; (e) CuSO₄·5H₂O, sodium ascorbate, L-proline, Na₂CO₃, NaN₃, H₂O/^tBuOH 1:1, 60 °C; (f) CuSO₄·5H₂O, sodium ascorbate, alkyne, H₂O/^tBuOH 1:1, room temp.




**Scheme 5.**


Synthesis of Compound **20**, 2-(4-Cyclopentylmethyl-1,2,3-triazol-1-yl)-N⁶-(2-chloro-5-methoxybenzyl)adenosine^a

^a Reagents and conditions: (a) 2-chloro-5-methoxybenzylammonium chloride, Et₃N, EtOH, reflux; (b) CuSO₄·5H₂O, sodium ascorbate, L-proline, Na₂CO₃, NaN₃, H₂O/BuOH 1:1, 60 °C; (c) CuSO₄·5H₂O, sodium ascorbate, alkyne, H₂O/BuOH 1:1, room temp.

Binding Affinities of Adenosine Derivatives at Human A₁, A_{2A}, and A₃ARs Expressed in CHO Cells and Relative Efficacy at the A₃AR^d

Table 1

	 1-11, 15-20			 12-14			 23, 31, 33		
	R ₁	R ₂	R ₃	K _i (nM) or % inhibition (in parentheses) at 10 μM	hA _{2A}	hA ₃	% efficacy ^b		
1	CH ₂ OH	H	CH ₃	1000 ± 30	(13 ± 3)	10.4 ± 0.2	41 ± 6		
2	CH ₂ OH	ethyl	CH ₃	2920 ± 910	(18)	13.8 ± 3.3	23 ^c		
3	CH ₂ OH	butyl	CH ₃	848 ± 76	(23)	11.7 ± 3.1	3 ± 8		
4	CH ₂ OH	2-hydroxyethyl	CH ₃	1270 ± 260	(14)	45.0 ± 4.4	25 ^c		
5	CH ₂ OH	dimethyl/laminomethyl	CH ₃	3800 ± 600	(6)	117 ± 25	8 ^c		
6	CH ₂ OH	phenyl	CH ₃	(36)	(5)	14.9 ± 1.7	14 ± 8		
7	CH ₂ OH	pyridin-2-yl	CH ₃	1970 ± 210	(40)	10.3 ± 1.5	11 ± 4		
8	CH ₂ OH	4-propoxyphenyl	CH ₃	(49)	(14)	25.2 ± 2.6	31 ^c		
9	CH ₂ OH	benzyl	CH ₃	589 ± 55	(20)	9.5 ± 0.7	-1 ± 5		
10 ^d	CH ₂ OH	cyclopentylmethyl	CH ₃	335 ± 13	(39)	1.3 ± 0.4	-5 ± 7		
11	CH ₂ OH	cyclohexylmethyl	CH ₃	1430 ± 60	(16 ± 1)	21.3 ± 8.1	2 ± 5		
12	CH ₂ OH	benzyl	CH ₃	770 ± 210	(21 ± 5)	53.9 ± 6.6	2 ± 3		
13	CH ₂ OH	3-methoxybenzyl	CH ₃	957 ± 65	(43 ± 10)	86.1 ± 3.8	-1 ± 3		
14	CH ₂ OH	3-Cl-benzyl	CH ₃	956 ± 6	(39 ± 10)	81.1 ± 5.0	0 ± 5		
15 ^d	C ₂ H ₅ NHCO	H	CH ₃	590 ± 70	(18 ± 3)	2.1 ± 0.1	102 ± 5		
16	C ₂ H ₅ NHCO	butyl	CH ₃	750 ± 110	(43 ± 1)	5.6 ± 0.2	89 ± 3		
17 ^d	C ₂ H ₅ NHCO	pyridin-2-yl	CH ₃	1640 ± 90	(45 ± 12)	1.8 ± 0.6	90 ± 7		
18 ^d	C ₂ H ₅ NHCO	benzyl	CH ₃	510 ± 50	(33 ± 2)	2.8 ± 1.3	86 ± 5		
19	C ₂ H ₅ NHCO	cyclopentylmethyl	CH ₃	1250 ± 150	(36 ± 7)	11.5 ± 1.4	83 ^c		



	R₁	R₂	R₃	K_i (nM) or % inhibition (in parentheses) at 10 μM			% efficacy^b
				hA₁	hA_{2A}	hA₃	
20	CH ₂ OH	cyclopentylmethyl	2-Cl-5-MeO-Bn	830 ± 40	6000	18 ± 11	-6 ± 3
23	CH ₂ OH		CH ₃	230 ± 10	(23)	10.8 ± 3.1	84 ± 9
31	C ₂ H ₅ NHCO		CH ₃	429 ± 55	(18 ± 3)	11.4 ± 4.2	112 ^c
33	CH ₂ OH		2-Cl-5-MeO-Bn	60 ± 10	1800 ± 500	1.4 ± 0.1	44 ± 5

^a All binding experiments were performed using cells stably transfected with cDNA encoding one of the human ARs. Binding at human A₁, A_{2A}, and A₃ARs in this study was carried out as described in Experimental Section using [³H]CCPA, [³H]CGS 21680, or [¹²⁵I]IAB-MECA as a radioligand. Values from the present study are expressed as K_i values (mean ± SEM, *n* = 3, unless otherwise noted) or as percent displacement of radioligand.

^b % activation at 10 μM, relative to cyclic AMP inhibitory effect of 10 μM NECA (= 100%). CI-IB-MECA was also a full agonist (100%) in this assay.

^c *n* = 2.

^d **10**, LC 153; **15**, LC 260; **17**, LC 257; **18**, LC 259.